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The anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are a group 35 
of disorders involving severe, systemic, small-vessel vasculitis and are characterized by the 36 
development of autoantibodies against the neutrophil proteins leukocyte proteinase 3 (PR3-37 
ANCA) or myeloperoxidase (MPO-ANCA). The three AAV subgroups, namely granulomatosis 38 
with polyangiitis (GPA), microscopic polyangiitis and eosinophilic GPA (EGPA), are defined on 39 
the basis of clinical features. However, genetic and other clinical findings suggest that these 40 
clinical syndromes may be better classified as PR3-positive AAV (PR3-AAV), MPO-positive 41 
AAV (MPO-AAV) and, for EGPA, by the presence or absence of ANCA (ANCA+ or ANCA–, 42 
respectively). Although any tissue can be involved in AAV, the upper and lower respiratory tract 43 
and kidneys are most commonly and severely affected. AAVs have a complex and unique 44 
pathogenesis, with evidence for a loss of tolerance to neutrophil proteins, which leads to ANCA-45 
mediated neutrophil activation, recruitment and injury, with effector T cells also involved. 46 
Without therapy, prognosis is poor, but treatments, typically immunosuppressants, have 47 
improved survival, albeit with considerable morbidity from glucocorticoids and other 48 
immunosuppressive medications. Current challenges include improving measures of disease 49 
activity and risk of relapse, uncertainty about optimal therapy duration and a need for targeted 50 
therapies with fewer adverse effects. Meeting these challenges requires a more detailed 51 
knowledge of the fundamental biology of AAV, and co-operative international research and 52 
clinical trials with meaningful input from patients. 53 
  54 
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[H1] Introduction 55 
 The anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) 56 
are diseases characterized by inflammation of blood vessels, endothelial injury and tissue 57 
damage. Three types of small-vessel vasculitis, namely granulomatosis with polyangiitis 58 
(GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis 59 
(EGPA, previously known as Churg-Strauss syndrome), feature a loss of tolerance to 60 
neutrophil primary granule proteins, most often leukocyte proteinase 3 (PR3; also known as 61 
myeloblastin) or myeloperoxidase (MPO) (Table 1). The vessels involved in AAV are 62 
typically capillaries, arterioles and venules, but small arteries and veins may also be affected. 63 
Autoimmunity is documented clinically by serum ANCAs against PR3 (PR3-ANCA) or 64 
MPO (MPO-ANCA), which are generally associated with the main syndromic AAV 65 
presentations (Box 1). AAVs collectively represent one of several types of autoimmune 66 
vasculitis (Figure 1). 67 
 GPA and MPA can involve small blood vessels in any organ or tissue, but commonly 68 
affect the upper and lower respiratory tract and the kidneys (Box 2). Patients with AAV 69 
typically present with severe organ-threatening or life-threatening disease, although less 70 
severe presentations also occur. GPA is predominantly associated with PR3-ANCA, and its 71 
clinical features typically include sinonasal disease, lower respiratory tract involvement with 72 
pulmonary haemorrhage and granulomatous inflammation, and glomerulonephritis. MPA is 73 
usually associated with MPO-ANCA, and clinical features include more severe renal disease 74 
and some of the manifestations of GPA but without granulomatous inflammation. EGPA is 75 
characterized by asthma, eosinophilia and, in many (but not all) cases, vasculitis. EGPA is 76 
less common than GPA or MPA and, in some cases, is associated with ANCAs, mainly 77 
MPO-ANCA (Table 1). Although categorized as a form of AAV, EGPA has less overlap with 78 
the other AAVs than that between GPA and MPA in its genetic, pathogenetic and clinical 79 
features, and management and is typically considered a separate entity. 80 
 81 
 Improvements in treatment and prognosis for patients with AAV have resulted from 82 
translation of both pre-clinical and clinical research findings. Here, we provide an updated 83 
overview of the clinical and molecular features of AAVs, present current pathophysiological 84 
concepts, discuss established and upcoming therapeutic options, emphasise the value of 85 
patient-oriented outcomes, and provide a perspective on future challenges in AAV research 86 
and treatment.  87 
  88 
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[H1] Epidemiology 89 
[H2] Incidence and prevalence 90 
 Although fulfilling most definitions of a ‘rare disease’, with a historical estimated 91 
prevalence of 48–184 cases per million persons1, rheumatologists, nephrologists, clinical 92 
immunologists and other physicians regularly encounter patients with AAV. In fact, more recent 93 
studies report rates of prevalence of between 300-421 per million persons2,3, an inflation likely 94 
explained by improving survival and better case definition. 95 
The global impacts of AAVs in terms of premature mortality4, quality of life (QOL)5 and 96 
societal economic costs6 are considerable. Since the introduction of commercially available 97 
ANCA assays in the mid-1990s and enhanced physician awareness, there has been a noticeable 98 
increase in apparent AAV incidence. For example, the incidence rate of GPA between 1975 and 99 
2001 in Sweden increased from 3.3 to 11.9 cases per million persons per year7. The plateauing 100 
of incidence rates since then indicates that the true incidence has likely remained stable, 101 
although the lack of standardized diagnostic criteria may affect case ascertainment.  102 
 There is wide geographical variation in AAV incidence (Figure 2), which is partly 103 
explained by methodological differences in study design, although specific patterns can be 104 
observed. First, GPA (PR3-AAV) mainly affects countries in which the population is 105 
predominantly of European ancestry and is seldom observed in East Asian countries. By 106 
contrast, MPA (MPO-AAV) predominates in Asian countries, such as China and Japan8,9. 107 
Second, the incidence of GPA is influenced by latitude, as the incidence is lower towards the 108 
equator10,11. The disparity in incidence among ethnicities is further supported by studies 109 
examining multi-ethnic populations. Surveys in France and USA both indicate at least a two-fold 110 
higher incidence of GPA and MPA in white populations than in other ethnicities12,13. A more 111 
recent UK study identified a similar signal, but this was mostly explained by the older age of the 112 
white population14. EGPA is strongly linked to asthma and eosinophilia in terms of both its 113 
clinical features and genetic make-up, though epidemiological data pertaining to EGPA are 114 
limited, as are data from Africa and South Asia for all types of AAV. It is unclear whether lack 115 
of access to ANCA testing in low-income and middle-income countries is resulting in not only a 116 
lack of data, but also under-diagnosis and under-treatment of AAV in these areas.  117 
 AAV in children is rare and less common than some other forms of vasculitis (including 118 
Kawasaki disease and IgA vasculitis). GPA seems to be more common than MPA or EGPA, and 119 
unlike adults, AAV in children is likely to be more common in females15. 120 
 121 
[H2] Risk factors and disease determinants 122 
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There is compelling evidence implicating genetic factors in the pathogenesis of AAV, although 123 
genetic predisposition alone does not explain this complex disorder. As the typical age of onset 124 
ranges between middle to older age and there is an equal sex distribution in AAV prevalence, it 125 
is likely that environmental factors have a key role in AAV aetiology. Some epidemiological 126 
studies report a cyclical occurrence of GPA, which is consistent with an infectious trigger. 127 
Although the majority of studies describe an increase in the incidence of GPA in winter16-19, a 128 
higher summer incidence and no seasonal change have also been reported 20,21. Indeed, increased 129 
rates of chronic Staphylococcus aureus nasal carriage, observed among patients with GPA have 130 
been associated with an increased relapse risk22,23. 131 
 More granular epidemiological inspections of putative environmental causes are limited 132 
to small exploratory studies. An association between silica exposure and MPO-AAV has been 133 
consistently observed24,25. The high prevalence of silica in the natural environment (for example, 134 
in cement) is one proposed explanation for the apparent upsurge in AAV incidence following 135 
major earthquakes in 1995 and 2011 in Japan26,27. However, this correlation was not replicated 136 
in the aftermath of the 2011 earthquake in Christchurch, New Zealand28, a discordance that 137 
potentially highlights the importance of AAV gene–environment interactions. Anecdotally, 138 
clinicians commonly observe a disparity in prevalence between urban and rural areas, although 139 
the epidemiological data to support this disparity are mixed29. For example, in a rural region of 140 
the UK, farming has been identified as a risk factor for both GPA and MPA24, indirectly 141 
implicating pesticide and fertilizer exposure as potential pathogenetic factors. By contrast, 142 
pollution, specifically carbon monoxide levels, has been associated with increased AAV risk in 143 
population-dense China30. Other postulated risk factors include UV light31, smoking32, solvents24 144 
and occupational solvent exposure24, but no single environmental factor seems to confer a major 145 
population-attributable risk. Similarly, specific drugs are responsible for some cases of vasculitis 146 
with syndromes similar to AAV (Box 3). 147 
 Ultimately, many epidemiological studies have treated AAV as a single disease construct 148 
and lack the power to examine the possibility that distinct environmental associations exist 149 
across the pathogenetically distinct sub-types.  150 
  151 
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[H1] Mechanisms/pathophysiology 152 
 AAVs are characterized by microvascular endothelial inflammation leading to 153 
extravascular inflammation, progressive injury, tissue destruction, fibrosis and loss of 154 
function. GPA and MPA develop by the loss of immunological T and B cell tolerance to one 155 
of two neutrophil proteins, PR3 or MPO. Mechanisms of acute injury in GPA and MPA are 156 
unique to this group of disorders and are overviewed schematically in Figure 3. Specifically, 157 
loss of tolerance leads to the development of ANCAs, autoantibodies that activate 158 
neutrophils. ANCA-activated neutrophils localize to vulnerable microvascular beds, where 159 
they induce injury and release the autoantigen for presentation by antigen-presenting cells 160 
(such as dendritic cells (DCs)), allowing antigen recognition by effector T cells that mediate 161 
further injury. Key elements of loss of tolerance, the generation of effector responses, and 162 
mechanisms of microvascular injury are summarized in Figures 4 and 5. 163 
 The pathogenesis of AAVs has been explored in in vitro assays and in vivo in animal 164 
models and in human studies. In animal studies, MPO-AAV is characterized by anti-MPO 165 
autoreactivity affecting the kidneys33. Although glomerular and pulmonary vessels are 166 
particularly vulnerable, there is little evidence to indicate why some vascular beds are 167 
preferentially involved. Furthermore, the mechanisms underpinning the frequent occurrence 168 
of granulomatous inflammation in PR3-AAV and its near absence in MPO-AAV are 169 
undefined. The response to injury, including the extent of tissue destruction and/or fibrosis, is 170 
likely to be contingent on the characteristics of the affected tissue, and the intensity and 171 
chronicity of local vasculitic inflammation. 172 
 173 
[H2] Genetics 174 
[H3] GPA and MPA. Evidence for a genetic contribution to the aetiology of AAVs has 175 
come largely from registry studies, which revealed that the familial relative risk (RR 1.56) is 176 
similar to that for rheumatoid arthritis (RR 1.5-5.0) but lower than that for other immune-177 
mediated diseases34. Identifying robust genetic associations with AAV is challenging due to 178 
its fairly low prevalence, although candidate gene studies that utilized cohorts combining 179 
patients with GPA and those with MPA, and occasionally those with EGPA, found 180 
associations with the major histocompatibility complex (MHC) genes, in particular the HLA-181 
DP*04:01 locus35. The European Vasculitis Genetics Consortium reported the first genome-182 
wide association study (GWAS) in AAV36, which identified both MHC and non-MHC 183 
associations with disease and demonstrated that GPA and MPA are genetically distinct. 184 
Moreover, sub-analyses revealed that the strongest associations were not with the clinical 185 
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syndromes per se, but with ANCA specificity. The Vasculitis Clinical Research 186 
Consortium37,38 confirmed these associations and provided the first evidence for genetic 187 
variants, for example in PTPN22, that are common to both PR3-AAV and MPO-AAV, 188 
suggesting there was also a shared genetic component to these diseases. How much of the 189 
clinical similarity between the two syndromes is driven by this shared genetic architecture, 190 
rather than antigenic similarity, awaits the outcome of larger GWAS that are better powered 191 
to assess associations with PR3-AAV and MPO-AAV separately. 192 
 Although the causal variant or variants at each locus remain unresolved, these genetic 193 
studies shed light on the underlying disease pathogenesis. Some variants represent genes, 194 
such as PTPN22 associated with other autoimmune diseases39, and larger studies are likely to 195 
identify further commonalities. Other variants are more specific to AAV. Genetic variants at 196 
both SERPINA1 (encoding α1-antitrypsin) and PRTN3 (encoding PR3) independently lead to 197 
increased plasma levels of PR3, suggesting that altered availability of circulating PR3 is a 198 
key driver in loss of tolerance to PR3 and the subsequent development of PR3-AAV. The 199 
association of HLA-DP*04:01 with PR3-AAV may simply reflect the role of HLA (MHC) in 200 
presenting PR3 peptides to the immune system. However, this HLA-DP molecule also binds 201 
to the natural killer (NK) cell receptor NKp44, leading to NK cell activation40, which might 202 
represent an alternative or additional mechanism that underpins the relationship between 203 
HLA-DP and PR3-AAV. 204 
[H3] EGPA. One GWAS examining EGPA has identified 11 loci associated with EGPA41 205 
and demonstrated that EGPA comprises two genetically distinct subtypes, MPO-ANCA+ 206 
EGPA and ANCA– EGPA These subtypes align with the clinical differences existing between 207 
these patient subsets42,43. Some of the identified loci are associated with eosinophil count in 208 
addition to EGPA, and Mendelian randomization revealed that increased risk of eosinophilia 209 
underlies susceptibility to EGPA, with additional genetic or environmental factors required 210 
for the development of disease. 211 
 212 
[H2] Environmental factors and infections 213 
 The increasing incidence of AAV in the sixth and older decades of life implies a role 214 
for age-related factors and various accumulating environmental factors (discussed above), 215 
although these factors remain ill-defined. Whereas some observational studies implicate 216 
infectious triggers in AAV pathogenesis, the precise infectious agents remain unclear. 217 
Mechanistic in vitro and in vivo animal model studies suggest several ways in which, 218 
infection might promote loss of tolerance or disease relapse in AAV. These include 219 
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autoantigen exposure by the formation of neutrophil extracellular traps (NETs) that may be 220 
resistant to degradation in AAV44, by molecular mimicry (that is, microbial antigens sharing 221 
sequence similarity with a host protein), and by the priming of neutrophils for ANCA-222 
induced activation33 (Figure 4). Some attention has focused on S. aureus, with reports of 223 
increased rates of nasal carriage in relapsing GPA patients 22 and experimental data 224 
implicating a plasmid-encoded 6-phosphogluconate dehydrogenase sequence from some S. 225 
aureus strains in by molecular mimicry in MPO-AAV45. 226 
 227 
[H2] ANCA antigens 228 
 As autoreactivity to either MPO or PR3 is central to the majority of cases of AAV, the 229 
characteristics of the key autoantigens are important. In most patients with AAV there is a 230 
single dominant autoantigen. MPO and PR3 are found primarily in neutrophils and are also 231 
produced by monocytes and macrophages. Although PR3 and MPO are mainly synthesized 232 
by immature neutrophils, altered DNA methylation and increased expression of PRTN3 and 233 
MPO in mature neutrophils is implicated in disease pathogenesis46. PR3 and MPO are not 234 
only key AAV autoantigens, they also have damaging effects on the endothelium in 235 
microvascular inflammation. They are released by multiple mechanisms, including by 236 
degranulation and microparticle release, and as constituents of NETs47. 237 
 PR3 is a 29kDa serine protease with pro- and mature forms48, which are located 238 
within azurophilic granules. The variable expression of PR3 on the surface of neutrophils is 239 
in part dependent on co-expression with CD177, which binds to and colocalizes with the b2 240 
integrin CD11b as part of the CD11b/CD18 complex49,50. Cell surface PR3 expression is 241 
increased in apoptotic neutrophils, which limits macrophage phagocytosis and promotes a 242 
pro-inflammatory microenvironment48. MPO is abundant in human neutrophils as a major 243 
component of azurophilic granules. Mature MPO is composed of light and heavy chains as a 244 
highly cationic homodimeric glycoprotein, bound to a haem group. The heavy chain is 245 
extensively but variably glycosylated51,52. Pro-inflammatory stimuli increase cell surface 246 
MPO levels, and MPO is released in inflammatory states, where it catalyses the formation of 247 
reactive intermediates, including hypohalous acids. The AAVs are typically considered 248 
systemic autoimmune diseases, each with dominant autoreactivity to only a single 249 
autoantigen. However other autoantigens have been associated with AAV, including 250 
lysosome-associated membrane protein 2 (LAMP2)53, peptides complementary to PR3 251 
(cPR3)54,55, moesin56, plasminogen57,58, peroxidasin59 and pentraxin 360. Infection has been 252 
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implicated in loss of tolerance to some of these antigens. In rats, a LAMP2 epitope, found in 253 
myeloid cells and endothelial cells, and homologous to part of the bacterial adhesin FimH, 254 
induces AAV53. Reactivity to cPR3, derived from the non-coding strand of PR3 cDNA, and 255 
potentially initiated after infection54, may trigger anti-PR3 autoreactivity. While several 256 
studies support a role for LAMP2 in MPA or GPA, or cPR3 in the pathogenesis of PR3-257 
AAV, not all reports implicate these alternative antigens in disease61,62. 258 
 259 
[H2] Loss of tolerance to ANCA antigens 260 
[H3] Central and peripheral mechanisms of tolerance. Central and peripheral mechanisms 261 
prevent damaging autoreactivity and autoimmune diseases by maintaining tolerance to self-262 
antigens. In most autoimmune diseases, loss of T cell tolerance allows the emergence of T 263 
helper (Th) cells, that are central to autoantibody production by cells of the B cell lineage, 264 
and also themselves promote tissue injury. Loss of B cell tolerance allows the emergence of 265 
autoreactive B cells and plasma cells that produce damaging autoantibodies. Memory T and 266 
B cells that develop over time are important in chronicity and relapse. This is the case in 267 
AAV (Figure 4). Loss of tolerance to neutrophil proteins occurs prior to the onset of 268 
symptoms of AAV63. Our understanding of this process is imprecise; whereas dysregulated 269 
neutrophil apoptosis might predispose to loss of tolerance, there is no clear evidence that this 270 
is essential. Defects in both central and peripheral tolerance are present in AAV. Central 271 
tolerance to antigens in AAV is imperfect, as autoantigen-specific T cells and ‘natural’ 272 
autoantibodies are present in healthy individuals64. In the thymus, critical for T cell tolerance, 273 
MPO expression is under the control of the autoimmune regulator (AIRE) and Aire-/- mice 274 
exhibit stronger autoimmunity to MPO65. However, AIRE-deficient individuals do not seem 275 
to develop AAV, consistent with the existence of multiple layers of tolerance to MPO. 276 
Animal studies support a role for regulatory T (Treg) cells in limiting autoimmune disease65, 277 
and patients with AAV have fewer Treg cells and regulatory B (Breg) cells, with Treg cells 278 
having a diminished capacity to suppress effector responses ex vivo66-69, with Treg cell 279 
abnormalities linked to antigen-specific effector IL-17-producing T helper (TH17)-like 280 
cells67,70. To better understand loss of tolerance, and to move toward harness tolerogenic 281 
therapeutic platforms, and more precise diagnostic tools and biomarkers, immunodominant T 282 
and B cell epitopes have been defined for MPO, but not for PR370-73. Conformational and 283 
linear B cell epitopes exist for both MPO-ANCA and PR3-ANCA74-76. An MHC-284 
promiscuous CD4+ T cell MPO epitope overlaps with a linear B cell epitope and a CD8+ T 285 
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cell epitope70-73, and is nephritogenic in mice. Knowledge of these epitopes enables 286 
translational strategies to improve disease monitoring and re-establish tolerance. 287 
 288 
[H3] Maintenance of autoreactive B cells. After the loss of tolerance, the survival of 289 
autoreactive lymphocytes promotes ongoing and chronic disease (Figure 4). In the case of 290 
AAV, B cell survival factor B cell-activating factor (BAFF) is produced by ANCA-291 
stimulated neutrophils and BAFF levels are elevated in AAV77,78, suggesting that interactions 292 
between BAFF and its receptors on autoreactive B cells and plasmablasts promote 293 
autoimmunity. After therapeutic B cell depletion, BAFF may promote relapse by promoting 294 
the recovery of autoreactive B cells. B cells and B cell aggregates are present in more chronic 295 
lesions, implying additional roles for antigen-specific B cells beyond antibody production, as 296 
pro-inflammatory cells or as antigen-presenting cells79,80. 297 
 298 
[H2] The role of ANCA and neutrophils 299 
[H3] ANCAs activate neutrophils and monocytes. 300 
 A critical consequence of loss of T and B cell tolerance is the production of ANCAs 301 
that bind to and activate neutrophils, so that they adhere in vulnerable microvascular beds and 302 
induce injury (Figures 3 and 5). ANCAs are usually of the IgG isotype, but IgA and IgM 303 
ANCA have also been reported81,82. ANCAs bind to their autoantigen, activate neutrophils 304 
and initiate injury83. In vitro studies support a model whereby both F(ab')2–antigen and Fc–305 
FcgR interactions are required, by G-protein-coupled pathways and SYK, respectively84,85. 306 
The effects of ANCAs on neutrophils include changes in adhesion molecule expression86,87, 307 
alterations in cytoskeletal proteins such as polymerization of F-actin88, and the generation of 308 
reactive oxygen species 89. Mediator release occurs by several mechanisms: degranulation, 309 
NET formation and the release of microparticles90. The release of cytokines, proteases and 310 
other molecules induces necrotizing crescentic glomerulonephritis in mice91. A report of 311 
placental MPO-ANCA transfer to a neonate with pulmonary haemorrhage and microscopic 312 
haematuria supports a role for ANCAs in AAV pathogenesis92. The in vivo pathogenicity of 313 
ANCA-activated neutrophils has been convincingly demonstrated in experimental MPO-314 
AAV91,93 and evidence also exists for PR3-AAV94,95. ANCA also activate monocytes ex vivo, 315 
as monocytes express PR3 and MPO, albeit to a lesser degree than neutrophils. Compared 316 
with studies in neutrophils, the pathogenic implications of any direct effects of ANCA on 317 
monocytes is less certain96,97. Whether the 5–10% of patients with GPA or MPA who are 318 
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ANCA– have a relevant autoantibody is unresolved. Patients may be MPO-ANCA+ but their 319 
ANCAs may react to an epitope that is masked in conventional assays72 or to other antigens, 320 
including LAMP298 or pentraxin 360. There are ANCA epitopes that are derived from 321 
pathogenic sequences as well as from endogenous proteins, while other factors, including 322 
ANCA sialylation and glycosylation may contribute to the inconsistent relationship between 323 
ANCA and disease activity72,99,100. 324 
[H3] Neutrophil priming and activation state. Although ANCAs may activate neutrophils 325 
without additional inflammatory signals, neutrophil priming by exogenous or endogenous 326 
proinflammatory signals promotes the damaging effects of these cells after ANCA-induced 327 
activation (Figures 3 and 4). In addition to the functional consequences of genetic variation in 328 
PRTN3 and its inhibitor SERPINA1101 and epigenetically mediated increases in PR3 and 329 
MPO46,102, neutrophils from AAV patients, even in remission, produce more intracellular 330 
reactive oxygen species, NETs and have a greater capacity to active the alternative pathway 331 
of complement (see below)103,104. The precise contributions of intrinsic properties of 332 
neutrophils and their response to priming events are unclear, but both are likely to be 333 
relevant. Neutrophil priming in AAV occurs by several mechanisms, of which the most well 334 
defined are the complement system (see below), toll-like receptors (TLRs) and cytokines 335 
(including TNF and IL-18)33. TLRs are expressed on several relevant cell types, including 336 
neutrophils, monocytes and microvascular endothelial cells. Engagement of TLRs by 337 
pathogen-associated molecular patterns (PAMPs) or in sterile inflammation by damage-338 
associated molecular patterns (DAMPs) activates neutrophils and the endothelium105-108. 339 
[H3] Complement activation via the alternative pathway 340 
 Complement, specifically the C5a receptor (C5aR), is a validated therapeutic target in 341 
acute AAV109-111. Evidence implicates neutrophil cell surface C5a–C5aR interactions in 342 
neutrophil priming and activation109,112-115. Although paracrine and autocrine sources of C5a 343 
are possible, circulating C5a may be more important116, and little evidence exists for a role 344 
for the membrane attack complex (which comprises the complement subunits C5b, C6, C7, 345 
C8 and C9)109 in neutrophil priming and activation. In addition to activating neutrophils, C5a 346 
enhances neutrophil retention in the microvasculature and promotes T cell antigen 347 
recognition by activating dendritic cells115. Three different pathways (classical, lectin and 348 
alternative) can be responsible for C5 activation, and in AAV evidence points to the 349 
alternative pathway being the key to pathological C5a/C5aR interactions. In mice, deficiency 350 
of Factor B (important to the alternative pathway), but not C4 (the classical/lectin pathway) 351 
was protective in experimental anti-MPO antibody induced glomerulonephritis112, while 352 
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Factor Bb immunostaining in glomeruli correlated with renal injury117. Though not 353 
prominent, complement deposition is present in some human kidneys in AAV and may also 354 
be relevant to tissue pathology118. Low serum C3 levels in AAV with renal involvement are 355 
associated with unfavourable outcomes119,120. Other potential roles for complement in AAV 356 
include damaging relationships with pattern recognition receptors and with pro-coagulant 357 
molecules118. 358 
[H3] ANCA-induced neutrophil recruitment to the microvasculature 359 
 ANCA-activated neutrophils mediate microvascular injury by adhering to 360 
microvascular endothelial cells in vulnerable tissues, via integrin–endothelial adhesion 361 
molecule and chemokine–chemokine receptor interactions (Figure 5). ANCA enhances 362 
contact between neutrophils and activated endothelial cells via b2 integrins and C–X–C motif 363 
chemokine receptor 2 (CXCR2) in flow chamber assays121. In vivo microscopy studies using 364 
inflamed post-capillary venules have shown incremental recruitment of ANCA-activated 365 
neutrophils, consistent with in vitro mechanisms122,123. However, in the glomerulus, the 366 
mechanisms of ANCA-induced neutrophil adhesion are dependent on the ANCA 367 
concentration, so it is mediated by b2 integrin at low ANCA levels, whereas a4 integrin 368 
mediates adhesion at high ANCA levels and without additional stimuli (such as 369 
lipopolysaccharide) that themselves induce glomerular leukocyte recruitment87. 370 
 371 
[H2] T cells and cellular immunity 372 
 In addition to humoral immunity, cellular immunity is important in AAV 373 
pathogenesis, as CD4+ T cells promote ANCA production and CD4+ and CD8+ cells 374 
recognise ANCA antigens deposited in peripheral tissues by activated neutrophils (Figures 3 375 
and 5). The class-switched, high-affinity nature of IgG ANCA implies T cell help via T 376 
follicular helper (TFH) cells124, the abundance of which is increased in GPA125. CD4+ T 377 
effector memory cell abundance is increased in the blood and urine in AAV126 and CD4+ and 378 
CD8+ cells are present in lesions127-129. Both TH1 and TH17 effector cytokine profiles have 379 
been observed in AAV130,131, including TH1 profiles in granulomatous lesions132. CD4+CD28– 380 
cytotoxic T cells found in the blood of patients with GPA are linked to cytomegalovirus 381 
(CMV) infection, which is itself associated with poor AAV outcomes133. Furthermore, 382 
subclinical CMV infection and reactivation in immunosuppressed AAV patients may impair 383 
immune responses to infection, as the antiviral drug valacyclovir improved vaccine responses 384 
in CMV seropositive AAV patients134. 385 
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 Analyses of CD8+ T cell transcriptomes of patients with active AAV at diagnosis 386 
reveal that patients can be stratified into two groups correlating with differences in long-term 387 
outcomes135. CD8+ and CD4+ T cell transcriptome data shows that reduced expression of 388 
genes linked to T cell exhaustion correlates with relapsing disease136. The correlation 389 
between exhaustion, with progressive loss of T effector function, and favourable disease 390 
outcome extends across a range of autoimmune and autoinflammatory diseases136 and implies 391 
that therapeutics targeting this process may improve the management of AAV. 392 
 Effector T cells participate in tissue injury in AAV. When ANCA-activated 393 
neutrophils localize to inflamed tissues, they release their autoantigen129,137. The widespread 394 
deposition of the autoantigens in AAV in inflamed tissues makes these antigens available for 395 
recognition by effector T cells. Experimental studies, largely in experimental anti-MPO 396 
glomerulonephritis demonstrate a role for MPO-specific cells of both TH17 (earlier) and TH1 397 
type (later)138, while CD8+ T cells also cause experimental injury73. 398 
 399 
[H2] Monocytes and macrophages 400 
 Macrophages are prominent in AAV lesions, are the most abundant cell type in 401 
glomeruli 128,129, and are important in both acute and chronic injury (Figure 5). ANCAs bind 402 
to intermediate monocytes that release pro-inflammatory cytokines and chemokines96,97, 403 
while experimentally, inflammatory monocytes participate in glomerular crescent 404 
formation139. Macrophages are activated by effector TH1 and TH17 cells at sites of injury, 405 
participate in granuloma formation, form macrophage extra cellular traps in tissues129 and in 406 
chronic inflammation profibrotic macrophages contribute to disease progression and damage. 407 
 408 
[H2] The pathogenesis of EGPA 409 
The pathogenesis of EGPA is not well understood. It is likely to be substantially different 410 
to both GPA and MPA, but the extent of the similarities and differences is unclear. Furthermore, 411 
the clinical presentations, genetic associations and the response to therapies between ANCA+ 412 
and ANCA– EGPA patients imply distinct elements to the pathogenesis of these forms of 413 
EGPA41-43. Genetic associations with genes that influence eosinophil numbers and those that 414 
underlie asthma are common to both ANCA– and ANCA+ patients. However, in ANCA– EGPA 415 
patients, the association with genes affecting barrier function (including GPA33) implies a role 416 
for mucosal dysfunction, whereas in ANCA+ EGPA patients, the HLA associations are 417 
consistent with ANCA+ EGPA being an eosinophilic autoimmune disease. 418 
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In addition to genetic studies, observational studies implicate eosinophil dysfunction in 419 
the pathogenesis of EGPA. Eosinophil mediated injury via the release of granule proteins itself 420 
can induce tissue resident cells to release pro-inflammatory mediators. Some of these tissue cell 421 
derived molecules, such as IL-25, affect both adaptive (type 2 T helper, TH2 cell) and innate 422 
(group 2 innate lymphoid cells, ILC2) lymphoid cells140. Both Th2 and ILC2 cells produce IL-5 423 
and IL-13 key cytokines that promote eosinophil proliferation and function141,142. IL-5’s role has 424 
been validated by trials of mepolizumab, an anti-IL-5 monoclonal antibody in EGPA143. TH2 425 
cell-associated chemokines, such as CC-chemokine ligand 26 (CCL26; also known as eotaxin 426 
3), enhance eosinophil recruitment142. Other T cell-associated cytokines are also elevated in 427 
patients with EGPA, but thus far there is no clear evidence that a particular pattern of cytokine 428 
or chemokine production characterizes ANCA+ or ANCA- EGPA. A direct relationship between 429 
MPO-ANCA and eosinophils has not yet been demonstrated in ANCA+ patients with EGPA. 430 
 431 
H2 Chronicity and relapse in AAV 432 
The pathogenesis of AAV is characterized by complex pathways to tissue injury and 433 
damage involving both humoral and cellular effector systems. Much of the work on the 434 
pathogenesis of AAV has been in systems modelling acute injury. Although largely 435 
unexplored, mechanisms operative in disease induction are also likely to be relevant to 436 
relapse. Some observational evidence points towards infection, in part related to chronic 437 
sinonasal mucosal damage, being important in relapse, and determinants of T cell activity and 438 
exhaustion may also be able to identify those at high risk of relapse. 439 
  440 
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[H1] Diagnosis, screening and prevention 441 
[H2] Diagnostic and classification criteria 442 
 Clear definitions of GPA, MPA, EGPA and other systemic vasculitides are provided by 443 
the updated 2012 Chapel Hill Consensus Conference (CHCC)144 which, as the name implies, 444 
was consensus driven and not data driven (Figure 1, Table 1). In 2006, an algorithm was 445 
developed for applying the 1990 American College of Rheumatology (ACR) classification, 1993 446 
CHCC definitions and ANCA specificity to streamline classification of patients with GPA, MPA 447 
and EGPA for epidemiological studies and clinical trial purposes, but cannot be regarded as 448 
providing diagnostic criteria for clinical practice145. The current Diagnostic and Classification 449 
Criteria for Vasculitis (DCVAS) study further develops classification and diagnostic criteria in 450 
AAV146. 451 
 452 
[H2] Clinical presentation 453 
 The different types of AAV share non-specific clinical features of systemic 454 
inflammation, such as weight loss, malaise, fatigue, arthralgia and myalgia relating to the 455 
systemic autoimmune pathophysiology (Box 2, Figure 6). These are frequently misinterpreted 456 
as infections, malignancies, depression or osteoarthritis, especially in older patients147. This is 457 
pertinent as some conditions such as infective endocarditis not only share clinical features 458 
with AAV but may also have a positive ANCA test by indirect immunofluorescence (see Box 459 
1). Although asthma is a typical early feature of EGPA, all forms of AAV can present with 460 
manifestations relating to small vessel vasculitic lesions and dysfunction of any organ148. A 461 
variety of organ systems and tissues are affected in AAV, albeit at different frequencies in 462 
GPA, MPA and EGPA (Figure 6). 463 
Necrotizing or granulomatous lesions can affect the ears, nose and throat (ENT) tract, 464 
and cause symptoms of chronic rhinitis, sinusitis or laryngitis. Similar processes in the 465 
respiratory tract, also including pulmonary capillaritis, present with shortness of breath, 466 
cough, and haemoptysis due to pulmonary haemorrhage (Figure 6). Cavitating lung nodules 467 
can be present. Ophthalmological manifestations include granulomatous orbital or retroorbital 468 
masses, anterior segment inflammation, retinal vasculitis or optic neuritis. A purpural or 469 
petechial rash is most common, with necrotizing dermal vasculitis and other non-vasculitic 470 
skin rashes also occurring. Kidney involvement usually presents as rapid-progressive 471 
glomerulonephritis with haematuria, proteinuria and hypertension. Interstitial nephritis 472 
without glomerular involvement occurs but is not common. The peripheral nervous system is 473 
typically affected by mononeuritis multiplex, due to focal vasculitis of the vasa nervorum. 474 
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EGPA is characterised by the near-universal presence of asthma, often for years prior 475 
to the onset of eosinophilia and eosinophilic tissue inflammation, and difficult to control 476 
asthma not infrequently persists even after treatment of EGPA. A subset of EGPA patients do 477 
exhibit frank vasculitis. EGPA affected tissues are similar to those affected to GPA and 478 
MPA, at different frequencies (Figure 6). In particular, cardiomyopathy due to eosinophilic 479 
myocarditis is not uncommon in EGPA and can be life-threatening. Some of the differences 480 
in the manifestations of EGPA and MPA/GPA, for example urticaria and eosinophilic 481 
pneumonia, align with its characteristic eosinophil-dominated inflammation. 482 
Some patients present with GPA or MPA limited to a single organ, such as the 483 
kidneys, ENT tract or lungs, which may represent the early stages of AAV. However, in 484 
MPO-ANCA+ patients isolated renal disease or isolated pulmonary fibrosis is not infrequent. 485 
The recognition of MPO-ANCA+ pulmonary fibrosis, that many be the sole manifestation of 486 
disease, as a feature of AAV has been of some interest149. It may be more common in 487 
Japan150,151, though it occurs in diverse geographical locations. MPO-ANCA associated 488 
pulmonary fibrosis may result from chronic low-grade pulmonary inflammation, but this is 489 
not clear. A minority of MPO-ANCA+ patients with MPA also have anti-glomerular 490 
basement membrane antibodies and exhibit a hybrid disease phenotype152, whereas people 491 
with systemic lupus erythematosus or systemic sclerosis can be MPO-ANCA+ and develop 492 
some features of AAV, especially the vasculitic pattern of glomerulonephritis153-155. As initial 493 
clinical presentations are diverse and often nonspecific, AAV is an infrequent but important 494 
differential diagnosis for many conditions across many medical disciplines. AAV can remain 495 
undiagnosed for months or years until ANCA testing is performed. In view of the rarity of 496 
AAV and the existence of mimics of vasculitis, the diagnosis should be reviewed 497 
periodically, particularly in cases of inadequate response to treatment or if not all disease 498 
manifestations are consistent with AAV. 499 
 Children with AAV can develop a similar range of clinical features to adults. 500 
Constitutional, ENT, renal and pulmonary manifestations are most commonly found at 501 
presentation15. However, some features may be more common in children. A French 502 
Vasculitis Study Group Registry based case control study, with most children having GPA, 503 
found that children were more likely to have fever at onset than adults156. Rates of renal 504 
involvement were similar, but myalgia and peripheral neuropathy were less common. 505 
Children were more likely to relapse than adults and more frequently accrued damage, 506 




[H2] Clinical syndromes and antigenic specificity 509 
 MPA and GPA are strongly associated with MPO-ANCA and PR3-ANCA, respectively, 510 
whereas EGPA can be either ANCA+ (mostly MPO-ANCA) or ANCA– (Table 1). Global 511 
variations in clinical manifestations reflect the relative rates of MPA (MPO-AAV) and GPA 512 
(PR3-AAV) discussed in Epidemiology (above), with for example, clinical features associated 513 
with MPA being more common in East Asia. Given the presence of overlapping signs and 514 
symptoms but also clear clinical differences (described in Table 1 and Box 2), another approach 515 
to disease classification is by the autoantigen involved (that is, PR3-AAV and MPO-AAV), 516 
although this approach also has limitations: ANCA can be negative, MPO-ANCA can be false 517 
positive in patients without vasculitis157, assay standardization is lacking, and not all countries 518 
have ready access to high quality assays. Nonetheless, genetic and other studies demonstrate that 519 
the clinical differences between PR3-AAV and MPO-AAV are greater than those between GPA 520 
and MPA36,158, indicating that from a pathogenetic perspective, antigen specificity is important. 521 
Furthermore, post hoc analyses of a large multicentre study suggest that PR3-ANCA+ patients 522 
may respond better to the biologic rituximab than to the immunosuppressants cyclophosphamide 523 
and azathioprine, whereas these treatments seem to be equally effective in MPO-ANCA+ 524 
patients159. ANCA specificity also predicts differences in long-term prognosis: PR3-ANCA+ 525 
patients are at higher risk of relapse than MPO-ANCA+ patients160. In EGPA, the presence or 526 
absence of ANCA in patients defines its two subtypes. Most patients with EGPA are ANCA-, 527 
but approximately 40% are (or have been) ANCA positive, almost always MPO-ANCA. 528 
Clinically, renal involvement and peripheral nerve involvement are more common in ANCA+ 529 
patients, with cardiomyopathy and possibly pulmonary infiltrates being more common in those 530 
who are ANCA- 42,43. 531 
 532 
[H2] Biomarkers 533 
 ANCAs are unique markers that support the classification and diagnosis of GPA, MPA 534 
and EGPA. The indirect immunofluorescence test has been the initial screening test for ANCA, 535 
but high-quality immunoassays are preferred161 (Box 1). The ANCA test is useful in monitoring: 536 
patients with persistently elevated ANCA, a reappearance of ANCA or an increase in ANCA 537 
level have an increased likelihood of relapse, though restarting or intensifying therapy based on 538 
ANCA alone is not recommended. This aligns with an association between earlier relapse and a 539 
higher frequency of memory B cells162, while a higher plasmablast percentage during remission 540 
is also predictive of relapse163. The acute-phase markers C-reactive protein and erythrocyte 541 
sedimentation rate are of limited use in evaluating disease activity due to their lack of 542 
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specificity. Other disease activity biomarkers, including urinary soluble CD163, are under 543 
evaluation for use in assessing disease activity but await validation for routine clinical use164-166. 544 
 545 
[H2] Assessment of disease activity and chronic damage 546 
 Patients with AAV should have access to medical specialists with expertise in the 547 
complex care of vasculitis, ideally in a multidisciplinary context. Where needed, early referral to 548 
specialists experienced in assessing specific organ systems involved in AAV improves the 549 
quality of disease assessment. Managing patients at, or in collaboration with a dedicated 550 
vasculitis center provides opportunities to participate in clinical trials.	Disease assessments in 551 
AAV should target activity, damage, prognosis and function or QOL167, Validated tools to assess 552 
disease activity include the Birmingham Vasculitis Activity Score (BVAS) and the Five Factor 553 
Score (FFS). The BVAS comprises ten systems (one general, eight organ-specific and one open) 554 
and is used in clinical research to assess disease activity, remission, response to therapy and 555 
flare168. Only items that are newly present or worsening over the preceding four weeks are 556 
recorded. Disease states of active disease, remission, and refractory disease are defined as 557 
follows: a BVAS score of 0 represents remission, ≥1 represents active disease, and refractory 558 
disease is active disease despite treatment. Consensus definitions have been recommended by 559 
the European League Against Rheumatism (EULAR) for disease activity states, including 560 
remission, response, refractory disease and relapse which can be useful for clinical trials and 561 
studies169. The 1996 FFS is based on serum creatinine, proteinuria, cardiomyopathy, 562 
gastrointestinal involvement, and central nervous system involvement, and has been validated 563 
for MPA and EGPA but not GPA. The revised 2009 FFS includes serum creatinine, age (>65 564 
years), cardiomyopathy, gastrointestinal involvement and absence of ENT manifestations (GPA 565 
and EGPA only) but this version requires validation170. To assess chronic damage, both from the 566 
disease itself and from treatments such as glucocorticoids, the Vasculitis Damage Index (VDI) 567 
predicts mortality risk and scores 10 systems, namely musculoskeletal, skin and mucous 568 
membranes, ocular, ENT, pulmonary, cardiovascular, the peripheral vasculature, 569 
gastrointestinal, renal and neuropsychiatric systems, with an eleventh category for other 570 
systems171. 571 
 The BVAS and VDI are approved by the Outcomes Measures in Rheumatology 572 
(OMERACT) group and EULAR as key outcome measures to record disease activity and 573 
damage, respectively, in clinical trials172. Measures of QOL are important in the assessment of 574 
AAV. Generic tools have thus far been used but AAV-specific instruments have been developed 575 




[H2] Association with cardiovascular events 578 
 An increased risk of a cardiovascular events has been documented in AAV patients173. 579 
Indeed, during 5-years of follow up of four European Vasculitis Study Group trials of GPA and 580 
MPA, 14% of patients suffered a cardiovascular event defined as cardiovascular death, stroke, 581 
myocardial infarction, coronary artery bypass graft, or percutaneous coronary intervention. PR3-582 
ANCA was associated with a reduced cardiovascular risk compared to MPO-ANCA or negative 583 
ANCA status174. 584 
Dysfunction of the immune and coagulation systems contribute to an increased risk of 585 
venous thromboembolism175, especially during active disease176. An increased incidence of 586 
venous thromboembolism, in both typical and atypical sites, and pulmonary embolism has also 587 
been reported in GPA, MPA and EGPA177. 588 
 589 
[H2] Role of imaging and biopsy 590 
 A chest X-ray helps dissect the underlying pathology in patients with pulmonary 591 
symptoms (Figure 6), although CT has a higher sensitivity in detecting pulmonary nodules, 592 
cavities and alveolar opacities, as well as masses in the retro-orbital space, paranasal sinuses and 593 
the mastoids178. Iodinated contrast agents are not required for these studies. High-resolution 594 
chest CT (HRCT) may be helpful for detecting interstitial pneumonia; a study of HRCT 595 
involving Japanese patients with MPA, all but three of whom had MPO-ANCA, demonstrated 596 
abnormalities in 93%, with 51% having interstitial pneumonia151. While dynamic expiratory CT 597 
and other modalities have been advocated as potentially useful in detecting subglottic stenosis or 598 
endobronchial disease179, advanced imaging techniques may not be widely available or may only 599 
available as research tools. 600 
The high diagnostic specificity for AAV of a positive ELISA test for MPO-ANCA or 601 
PR3-ANCA, may in the appropriate clinical setting, preclude the need for biopsies. However, 602 
renal, lung, skin or other tissue biopsy is often important in establishing the diagnosis and may, 603 
especially in the case of nasal biopsy, provide the first evidence for AAV, particularly GPA. In 604 
the appropriate clinical context, granulomatous rhinitis or pneumonitis, and ‘pauci-immune’ 605 
glomerulonephritis are more specific for AAV than dermal leukocytoclastic vasculitis. 606 
Ultrasound-guided percutaneous kidney biopsy, while not mandatory, in the presence of 607 
haematuria and/or proteinuria can help make an initial diagnosis of AAV. Kidney biopsy can 608 
also diagnose relapse, establish the degree of chronicity of nephritis, and in chronic disease may 609 
be useful in determining whether impaired kidney function and proteinuria is related to active 610 
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vasculitis or irreversible damage. Biopsy samples from patients with suspected AAV should be 611 
assessed by an experienced pathologist. 612 
 613 
[H2] Pathology 614 
 615 
 Although sharing many features, the different forms of AAV show histopathological 616 
differences (Figure 7). Fibrinoid necrosis and inflammation of small vessels, sometimes 617 
accompanied by thrombosis, is the hallmark of acute injury in all forms of AAV180. In MPA, 618 
these features are present without other defining features, such as the granulomas in GPA or the 619 
prominent eosinophilic infiltrates in EGPA. Chronic lesions are characterized by transmural 620 
scarring with loss of the elastic internal lamina. Larger blood vessels can be affected, with 621 
leukocytic infiltrates and fibrinoid necrosis, as seen in polyarteritis nodosa. However, the 622 
involvement of larger vessels should not be interpreted as an ‘overlap’ with other forms of 623 
vasculitis when small vessel (capillary and arterioles) involvement is also present. While the 624 
histopathology of EGPA features necrotizing small-vessel vasculitis (as in GPA and MPA), an 625 
abundance of eosinophils is its defining feature. In the early stages of disease, eosinophilic 626 
infiltrates (but no necrosis) are present in tissues or in blood vessel walls, whereas in later stages 627 
of disease, eosinophils also surround the epithelioid cells within granulomas, and necrosis is 628 
present. 629 
 630 
[H3] Renal involvement. In the kidneys, the characteristic lesion in AAV is segmental necrosis 631 
of glomerular capillary loops, with little or no deposition of immunoglobulin or complement, 632 
termed ‘pauci-immune’ focal necrotizing (and crescentic) glomerulonephritis. Different lesions 633 
in different glomeruli within the same biopsy specimen reveal the asynchronous nature of the 634 
vasculitic injury. Acute glomerular injury is characterized by segmental necrosis with 635 
extravasation of fibrin and erythrocytes into the urinary space, followed by proliferation of 636 
parietal glomerular epithelial cells forming a cellular crescent. Destruction of Bowman’s 637 
capsule, the basement membrane surrounding the glomerulus, results from glomerular and 638 
periglomerular inflammation. These inflammatory changes lead ultimately to glomerulosclerosis 639 
that can be either segmental or global and represent the evolution of injury over days to months. 640 
 Glomerular lesions are used to stage renal disease in AAV by a histopathological 641 
classification181, where the dominant lesion is linked to outcomes. There are four patterns of 642 
injury, namely sclerotic (≥50% globally sclerosed glomeruli, worst outcome), focal (≥50% 643 
normal glomeruli, best outcome), crescentic (≥50% cellular crescents, intermediate outcome) 644 
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and mixed (no single dominant type of lesion, outcome better than the sclerotic but worse than 645 
the crescentic class). In clinical settings, this classification has been validated by some but not all 646 
studies, especially with regard to prognosis in the crescentic and mixed classes182. The 647 
classification does not currently include the extent of tubulointerstitial lesions or renal function. 648 
A further classification system has been proposed that includes these factors, together with the 649 
proportion of normal glomeruli at biopsy183. 650 
 Glomerular injury is often accompanied by inflammation of small arteries and a variable 651 
interstitial infiltrate around necrotic lesions, either glomeruli or blood vessels, in a granuloma-652 
like pattern, but multinucleated giant cells are rarely seen. The presence of sarcoid type 653 
granulomas in renal biopsies should lead to consideration of other diagnoses, such as renal 654 
sarcoidosis or an allergic drug reaction. 655 
[H3] Respiratory tract involvement. In GPA, upper and lower respiratory tract injury 656 
classically involves granulomatous inflammation. Small granulomas are composed of sometimes 657 
loose aggregates of epitheloid cells. The granulomatous inflammation often shows central 658 
necrosis containing nuclear fragments of granulocytes, is surrounded by a palisade of epithelioid 659 
cells and, in EGPA, by large numbers of eosinophils. Granulomatous inflammation and areas of 660 
necrosis are often confluent, with a ‘geographic’ appearance at low magnification. 661 
Multinucleated giant cells are almost invariably present and are pathognomonic for GPA or 662 
EGPA when seen in isolation in lung or upper airway biopsy samples, cytology specimens from 663 
bronchoalveolar lavage or nasal swabs taken when clinical features suggestive of AAV are 664 
present.  665 
 666 
 In the lungs, neutrophilic capillaritis is common to all forms of AAV. As vasculitic 667 
changes can be difficult to detect in small biopsy samples, samples should also be stained with 668 
trichrome and Elastica van Gieson for optimal detection of any disruption to alveolar or vessel 669 
walls, small areas of necrosis in arterioles and arteries, vascular inflammation, and characteristic 670 
scars affecting the full thickness of the vessel wall, which indicate past injury. Acute injury may 671 
consist of only non-specific inflammation or features resembling bronchiolitis obliterans and 672 
organizing pneumonia. However, signs of recurrent alveolar haemorrhage with extravasation of 673 
erythrocytes, variable numbers of siderophages or small areas of fibrin, necrosis or micro-674 
abscesses are suggestive of AAV. In the nose, necrotizing granulomatous inflammation in GPA 675 
can cause severe soft tissue destruction, including of the nasal cartilage. Large ulcers with 676 
denuded epithelium can be seen. Granulomatous inflammation is also a feature of nasal 677 
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involvement in EGPA, sometimes with eosinophilic necrosis but more often containing 678 
epithelioid cell aggregates surrounded by a dense eosinophil infiltrate. 679 
[H3] Other organ and tissue involvement. Similar vasculitic changes are found in other 680 
tissues, such as the heart, brain or gastrointestinal tract. In the gut, the finding of otherwise 681 
unexplained necrosis or haemorrhagic infarction should prompt extensive examination of 682 
mesenteric vessels for vasculitis. Although most often seen in isolation, dermal leukocytoclastic 683 
vasculitis can represent systemic disease. Involvement of the peripheral nervous system as 684 
mononeuritis or mononeuritis multiplex is due to ischaemia caused by vasculitic inflammation 685 
of the vasa nervorum184. 686 
 687 
[H2] Prognosis 688 
 The 5-year survival rates for AAV have been steadily rising to around 70–80% over the 689 
past 40–50 years, following the introduction of immunosuppressant therapies, increasing know-690 
how in the their use, and the introduction of ANCA testing, which are promoting earlier 691 
diagnosis and improvements in supportive care185. Data also suggest that there are ongoing 692 
improvements in mortality and end-stage kidney disease rates over the past decades in the 693 
USA186,187. Globally, AAV mortality rates, based on World Health Organisation International 694 
Classification of Diseases, 10th Revision (ICD-10) data are falling188. These data, though 695 
imperfect include mortality rates from many countries, and suggest similar age-standardised 696 
mortality rates in North America and Europe, with lower rates in Latin America and higher rates 697 
in Oceania. Data from Asia and Africa were limited. 698 
Initial clinical factors influencing outcomes include older age, severity of renal 699 
dysfunction, the presence of pulmonary haemorrhage (in some series), and disease activity 700 
measured by BVAS185; the findings on renal biopsy reflect severity of renal dysfunction and 701 
correlate with outcomes181. The 2009 FFS can also be applied to prognosis, since four factors are 702 
associated with a poor prognosis (age, renal insufficiency, cardiac involvement, and 703 
gastrointestinal manifestations, where each is accorded +1 point); the fifth factor, ENT 704 
manifestations, is associated with a better outcome and the absence of ENT symptoms scores +1 705 
point170. Ongoing factors influencing survival include infectious burden, development of first 706 
relapse within one year and the amount of chronic damage measured by the vasculitis damage 707 
index (VDI)174. As the VDI encompasses both disease and treatment-related damage, the risks of 708 
immunosuppressant drugs and glucocorticoids will also have an impact. Finally, other factors 709 
seem to influence the likelihood of relapse, currently quoted as ~50% by five years after 710 
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diagnosis; these include a diagnosis of GPA, presence of PR3-ANCA and upper or lower 711 
respiratory involvement189. 712 
  713 
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[H1] Management 714 
 Following diagnosis, disease assessment in AAV should consider activity and 715 
damage, for which assessment tools are available (see Assessment of disease activity and 716 
chronic damage section above), prognosis (see above), and function or QOL (described 717 
below). Broadly speaking, therapy can be divided into a phase aiming to induce remission 718 
with more intense therapy and a subsequent period where the goal is to maintain remission 719 
(Figure 8; clinical trials in GPA and MPA are summarized in Table 2). The goal of induction 720 
therapy is to achieve remission by 3 months that is sustained. Later remission, early relapsing 721 
or refractory disease is associated with worse outcomes190. 722 
 Treatment should be initiated as soon as a diagnosis of AAV is at least probable and 723 
appropriate safety investigations have been performed, as delays in diagnosis and treatment 724 
lead to worse outcomes. Initiation of treatment, especially in the setting of severe renal or 725 
lung disease, should not be delayed obtaining a biopsy, as several days of treatment usually 726 
does not markedly reduce the diagnostic yield of a biopsy. 727 
 728 
[H2] Remission induction 729 
 Prior to initiation of therapy there should be an assessment of any coexisting infection 730 
and any risk of infection, including screening for chronic viral infections, immunodeficiency, 731 
and for the risks of glucocorticoids, such as diabetes mellitus, osteoporosis, and psychiatric 732 
disorders. 733 
[H3] Glucocorticoids. Oral glucocorticoids (such as prednisone, prednisolone and others) are 734 
commenced when a diagnosis of AAV seems probable. These drugs exert a rapid effect. The 735 
initial dose for severe disease is 1 mg/kg daily of prednisone (or equivalent). The PEXIVAS 736 
trial demonstrated that a regimen that rapidly reduces the dose to 20 mg daily by 7 weeks and 737 
5 mg daily by 19 weeks is as effective and safer than more traditional, higher-dose 738 
regimens191. Glucocorticoids are the major modifiable cause of adverse events during the 739 
induction period and lower-dose regimens reduce severe infection rates. There is no 740 
consensus for glucocorticoid dosing in non-severe disease and lower initial doses may be 741 
used. The RITAZAREM trial demonstrated that patients with relapsing disease respond well 742 
to lower initial doses, such as 0.5 mg/kg/day, whether or not they had severe disease192. 743 
Intravenous pulse methylprednisolone (total dose 1–3 g) at the initiation of therapy for severe 744 




[H3] Other immunosuppressive or immunomodulating drugs. The combination of 747 
glucocorticoids with either cyclophosphamide or rituximab is the current standard of care for 748 
induction of remission for severe disease, although as further evidence supporting the 749 
efficacy of rituximab emerges, it is becoming the preferred induction agent for many patient 750 
subgroups, such as children and adults for whom the preservation of fertility is important, 751 
PR3-ANCA+ patients and in relapsing disease. However, rituximab is more expensive and 752 
globally is not as available as cyclophosphamide. Cyclophosphamide dosing is either by 753 
intermittent intravenous pulse treatments or by a daily oral dose. Doses are reduced for 754 
increasing age and renal impairment; either regimen is usually discontinued after 3–6 months, 755 
with subsequent initiation of therapy to maintain remission. Close monitoring is essential to 756 
minimize the risk of myelotoxicity. Intravenous regimens deliver ~50% of the cumulative 757 
dose compared to daily oral, with similar remission rates, but lower cyclophosphamide 758 
exposure is associated with a higher subsequent relapse risk193,194. 759 
 In two randomized trials, rituximab was non-inferior to cyclophosphamide for 760 
induction of remission and, in a post-hoc analysis of the RAVE trial, superior for patients 761 
with PR3-ANCA+ or relapsing disease159,195,196. These trials used 375 mg/m2, weekly for four 762 
doses, although two 1,000 mg doses (two-week interval) is also widely used. There is a 763 
paucity of comparative data on the use of either cyclophosphamide or rituximab in patients 764 
with low GFR (for example, <20 ml/min), with a lower dose of cyclophosphamide together 765 
with rituximab being used in the RITUXVAS trial197. The use of this combination is 766 
controversial and may confer an additional risk of infection198. 767 
 For non-severe disease, alternative immunosuppressive agents to cyclophosphamide, 768 
such as methotrexate and mycophenolate mofetil, are equivalent to cyclophosphamide in 769 
terms of remission rates at 6 months but have higher subsequent rates of relapse and greater 770 
accrual of damage, especially for PR3-ANCA disease. Methotrexate has been recommended 771 
for patients with no threat of organ-damaging disease, although longer term outcomes (such 772 
as relapse and damage accrual) are worse than with cyclophosphamide199. Such patients are 773 
uncommon and often require later use of cyclophosphamide or rituximab for control of more 774 
severe or relapsing disease. The MYCYC trial found similar responses for MPO-ANCA+ 775 
patients between mycophenolate mofetil and cyclophosphamide, at both 6 and 18 months200, 776 
and two other small randomized trials support a role for this agent as an alternative for this 777 
subgroup. 778 
[H3] Adjunctive therapy. Although smaller studies demonstrate that use of plasma 779 
exchange is associated with reduced risk of end-stage kidney disease for patients with a 780 
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serum creatinine >500 µmol/l at diagnosis201, the results of the large PEXIVAS trial indicate 781 
that plasma exchange should not be routinely recommended for GPA or MPA with nephritis 782 
or lung haemorrhage191. Whether specific subgroups, such as those that are oliguric at 783 
presentation or with hypoxic respiratory failure, benefit from plasma exchange requires 784 
further study. In one study, high-dose intravenous immunoglobulin (2 g/kg total dose) 785 
improved disease control of AAV refractory to usual therapy202 and can be considered when 786 
conventional agents are contraindicated, such as in the setting of severe infection. 787 
 788 
[H2] Therapy to maintain remission 789 
 The goals of maintenance therapy are to prevent relapse, to minimize the risk of 790 
comorbidities and drug toxicity, and to manage the consequences of organ damage, such as 791 
chronic kidney disease. Many patients with AAV require prolonged low-dose glucocorticoids 792 
(prednisone ≤10 mg daily) to maintain remission, even if also treated with rituximab or an 793 
oral immunosuppressive drug. 794 
 In the MAINRITSAN and RITAZAREM trials of interval treatment, rituximab was 795 
superior to azathioprine192,203. These findings are consistent with previous observational data 796 
and are driving a revision of guidelines. Azathioprine, methotrexate or mycophenolate 797 
mofetil, with or without oral glucocorticoids, can be used after cyclophosphamide to maintain 798 
remission in AAV. The optimal duration for treatment with these agents is uncertain, with the 799 
REMAIN trial supporting 3–4 years of treatment regardless of ANCA subtype or 800 
positivity204. The MAINRITSAN trial results indicate that following use of 801 
cyclophosphamide in patients with new-onset disease, a reduction in relapse rates occurs with 802 
use of rituximab (500 mg every six months over 2 years) compared with azathioprine. 803 
MAINRITSAN3 showed that following the initial two years of treatment, a further two years 804 
of rituximab treatment also reduced relapse rates205. The RITAZAREM trial confirmed and 805 
extended these observations in a cohort of patients with relapsing disease in whom remission 806 
was re-induced with rituximab and glucocorticoids, with maintenance rituximab at 1000 mg 807 
every four months over two years192,206. Both the MAINRITSAN trial results and 808 
observational data point to an increase in relapse risk after rituximab withdrawal, compared 809 
with continuing treatment, with a mean time to flare of two years after the last rituximab 810 
dose207. 811 
 There remains widespread use of oral immunosuppressive drugs after induction of 812 
remission with cyclophosphamide, at least until first relapse. The use of either CD19 counts 813 
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or serum ANCA levels to guide redosing of rituximab is controversial; a randomized trial 814 
comparing fixed-interval to biomarker-based dosing showed similar efficacy of these dosing 815 
regimens and reduced frequency of redosing, but more relapse when based on biomarkers208. 816 
 Several factors have been shown to alter the risk of relapse in AAV, including disease 817 
phenotype (GPA relapses more than MPA), ANCA subtype (patients with PR3-ANCA 818 
relapse more than patients with MPO-ANCA), a history of previous relapses, the presence of 819 
ENT disease, and the absence of severe renal disease207. Following induction therapy, 820 
persisting or the return of ANCA positivity, S. aureus infection, and lower cyclophosphamide 821 
exposure are linked to increased risk of relapse, but confirmation of these findings and testing 822 
in a clinical trial setting are needed prior to routine application to practice. As withdrawal of 823 
therapy appears to increase risk of relapse, patient-level factors to consider around drug 824 
withdrawal are the likely consequences of relapse (for example, end-stage kidney disease in a 825 
patient with chronic kidney disease), adherence to monitoring, access to expert advice, and 826 
patients’ views on the risks of relapse and ongoing drug exposure. 827 
 828 
[H2] Treatment of relapses of GPA and MPA 829 
 Continued regular monitoring of patients with AAV after induction of remission 830 
enables early detection of relapses with less advanced symptomatology than at presentation 831 
and reduced delay. When a patient is considered to be having a relapse, a review of the 832 
primary diagnosis and vasculitis mimics such as infection, malignancy or recreational drug 833 
use, should be excluded. Non-adherence to prescribed medications is also often a concern. 834 
One-third of relapses are severe with consequences for renal and patient survival. Treatment 835 
of relapse follows the same principles as for initial therapy, but rituximab is preferred in view 836 
of superior responses in the RAVE trial in relapsing patients and the beneficial effects seen in 837 
the RITAZAREM trial192,195,196. 838 
 839 
[H2] Treatment of refractory disease 840 
 Refractory disease in AAV has been defined as a failure to achieve full control of the 841 
vasculitis-related disease activity by six months, progressive disease within the first three 842 
months or relapse despite adequate ongoing therapy for maintenance of remission. It is 843 
important to differentiate true ‘failure’ of a medication from non-adherence, disease damage 844 
or mimics of vasculitis. This is most relevant in respiratory tract disease in which 845 
comprehensive assessment and treatment of any infection should accompany the evaluation 846 
of the vasculitis. An increase in glucocorticoid dose, such as use of intravenous 847 
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methylprednisolone, is used in severe disease relapse but prolonged use of high-dose oral 848 
glucocorticoids should be avoided due to the associated risks. Switching from 849 
cyclophosphamide to rituximab can be considered. Adjunctive therapies to consider are 850 
plasma exchange or intravenous immunoglobin (discussed above). 851 
 852 
[H2] Treatment of EGPA 853 
 The approach to patients with EGPA with severe disease is similar to that in GPA and 854 
MPA (Table 3). Treatment strategies for EGPA vary according to disease manifestations and 855 
severity, and concomitant manifestations of asthma should be managed assertively. The Five 856 
Factor Score is used to stratify people with EGPA, and the presence of substantial renal 857 
involvement (severe proteinuria or impaired kidney function), cardiomyopathy, 858 
gastrointestinal involvement, or central nervous system involvement indicates a need for 859 
more intensive treatment, such as a cyclophosphamide and glucocorticoid regimen analogous 860 
to that used in GPA and MPA. Although one trial failed to demonstrate a benefit of oral 861 
immunosuppressive drugs in non-severe disease209, these agents are widely used in an 862 
attempt to reduce the high glucocorticoid requirement typical for this disease. The anti-IL-5 863 
monoclonal antibody mepolizumab is a further therapeutic option that has demonstrated 864 
effects on airways and allergic manifestations143. In a randomised clinical trial, mepolizumab 865 
was useful in most patients, especially for asthma and sinonasal disease, either by 866 
maintaining sustained remission, reducing relapse rates or substantially reducing the dosage 867 
or duration of glucocorticoid therapy210. Rituximab can also be used in EGPA, but its efficacy 868 
in EGPA is less well established than for GPA and MPA, particularly for EGPA ANCA– 869 
patients, who show frequent relapse of asthma and sinonasal disease despite continued use of 870 
rituximab211. 871 
 872 
[H2] Monitoring disease activity 873 
 Clinical assessment and investigation follow the goals of maintenance outlined above, 874 
namely early identification of return of disease activity, screening for drug toxicity, and 875 
management and recognition of comorbidities. Serum creatinine measurement and urine 876 
analysis to detect haematuria and proteinuria should be undertaken regularly to assess disease 877 
activity and kidney function. Additional elements include patient education and psychosocial 878 
support. Lower baseline IgG levels are associated with increased risk of immunodeficiency 879 
after rituximab treatment. IgG levels should be checked periodically after treatment and 880 
falling levels should influence the decision on repeat dosing. Routine CD19 counts (a 881 
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measure of B cell levels) are not required but may be informative in patients with incomplete 882 
response to rituximab or early relapse. Microbiological assessment of the nasopharynx and 883 
infection control with topical antiseptic agents or antibiotics may improve symptomatic 884 
management. More intensive monitoring may be required for organ-specific issues, such as 885 
bronchoscopy in tracheo-bronchial disease, repeat renal biopsy in advanced renal impairment 886 
with persisting urinary abnormalities, and cardiac imaging (echocardiography and MRI) in 887 
cases of cardiac involvement  888 
 889 
[H2] Comorbidities and treatment effects  890 
 Infection is the most frequent serious problem in the first year of treatment for AAV. 891 
Routine prophylaxis against Pneumocystis jirovecii pneumonia with sulfamethoxazole-892 
trimethoprim (or alternative agents) is recommended and this treatment may also reduce the 893 
frequency of other bacterial infections. Independent of its value in Pneumocystis jirovecii 894 
prophylaxis, there is not enough evidence to recommend routine use of long-term 895 
sulfamethoxazole-trimethoprim in PR3-ANCA+ patients to prevent disease relapse. 896 
Avoidance of severe drug-induced leukopenia is crucial. Rituximab-induced 897 
immunodeficiency and any case of recurrent infection requires further immunological 898 
assessment. Cases of hypoimmunoglobulinaemia with frequent infections may prompt use of 899 
replacement immunoglobulin212. Routine vaccination against influenza and pneumococcal 900 
infection is recommended for all patients, although serological responses may be impaired, 901 
especially following rituximab treatment. 902 
 Venous thromboembolism should be treated with anti-coagulation agents, although 903 
these can be problematic in the setting of pulmonary haemorrhage213. The risk of 904 
cardiovascular events is markedly raised in patients with more extensive disease, those 905 
without PR3-ANCA, and in the presence of renal impairment173,214. There is no current 906 
advice concerning reducing these risks that is specific to patients with AAV, although careful 907 
attention to management of hypertension and hyperlipidaemia is recommended. 908 
 Cyclophosphamide and other oral immunosuppressive drugs are associated with an 909 
increased risk of malignancies, particularly non-melanoma skin cancer and urothelial 910 
malignancy215,216. The rates of these cancers are falling with reduced immunosuppressant 911 
exposure, especially to cyclophosphamide, and the increased use of rituximab217. The relative 912 
risk of malignancy increases with therapy duration, so screening for haematuria in patients 913 
exposed to cyclophosphamide and for skin malignancy should be lifelong. Prophylaxis 914 
30 
 
against gastric toxicity is often prescribed with high dose glucocorticoids, that also increase 915 
the risk of osteoporosis218. 916 
 The management of organ damage in patients with AAV requires sub-specialist 917 
intervention by those with appropriate experience, in co-ordination with the primary physician 918 
overseeing the treatment of the vasculitis. Examples include surgical correction of lacrimal duct 919 
obstruction, middle ear disease, nasal collapse and subglottic or endobronchial stenosis219. Renal 920 
transplantation is generally successful in AAV, although opportunistic infections may be more 921 
common than in transplant recipients without AAV, reflecting the prior burden of 922 
immunosuppressive therapy for AAV. Recurrence of vasculitis in the renal graft occurs in 2% of 923 
transplant recipients with AAV and can lead to graft failure. Long-term patient survival is 924 
similar to that of all causes of end-stage renal disease220.  925 
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[H1] Quality of Life 926 
 Patients are well aware of the challenges they face in managing AAV and self-report 927 
substantial impact on QOL from AAV itself as well as the burden of treatment and treatment-928 
related toxicities (Box 4). The evolution in immunotherapeutics has converted AAV into a 929 
chronic disease and in consequence, patient priorities have realigned. Rather than focus on the 930 
spectre of major organ damage, patients rank QOL domains, such as fatigue and pain, as the 931 
greatest disease priorities221. 932 
 There can be key differences between patient and clinician perceptions of these priorities. 933 
For example, although patients and clinicians both rank weight gain as a major concern about 934 
glucocorticoid treatment, patients frequently cite ‘moon face’ and other effects on appearance as 935 
highly concerning, whereas clinicians tend to not consider these effects to be as important as the 936 
risk of infection. A closer assessment of patient reported QOL will provide an opportunity for 937 
better alignment of patient and clinician priorities. 938 
 Characterization of a national cohort indicated that patients with AAV experienced 939 
substantially poorer levels of physical and mental QOL compared to matched controls in the 940 
general population (physical QOL: OR 7.0, 95% CI 4.4–11.1; mental QOL: OR 2.5, 95% CI 941 
1.7–3.6), even though the vast majority (80%) of patients had achieved disease remission5. 942 
 Modern induction agents certainly result in noticeable improvements in QOL, but gains 943 
are modest and patient QOL rarely returns to normal levels195. Several factors may explain this 944 
situation. First, high-dose glucocorticoids remain integral to standard care but they have multiple 945 
toxic effects, including on QOL domains such as mental health222, which should be assessed 946 
using, for example, the Glucocorticoid Toxicity Index223. Second, almost all studies of QOL in 947 
patients with AAV have used generic questionnaires, including the 36-item Short Form Health 948 
Survey (SF-36), the EuroQol-5 Dimension (EQ-5D) and the Health Assessment Questionnaire, 949 
which may not capture AAV-specific issues.  950 
The OMERACT Vasculitis Working Group developed a 29-item tool, the AAV-PRO 951 
questionnaire 224,225, covering six domains (organ-specific symptoms, systemic symptoms, 952 
treatment side effects, social and emotional effect, concerns about the future and physical 953 
function), following patient qualitative interviews to address this unmet need. The AAV-PRO is 954 
being integrated into ongoing randomized controlled trials. Similarly, the Patient-Reported 955 
Outcomes Measurement Information System (PROMIS), covers fatigue, physical functioning 956 
and pain interference. Both PRO systems assess function and QOL, are complementary and 957 
require further validation, but they offer options to ensure patients’ perspectives are considered 958 
when assessing disease activity in AAV224,225. 959 
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Impairments in QOL are the result of multiple factors, not only active inflammatory 960 
disease but also disease damage, although they seem to be primarily related to psychosocial 961 
factors, such as fatigue and dysfunctional coping strategies5 and skeletal dysfunction. 962 
Persistently high levels of fatigue that does not change after treatment occurred in some patients 963 
in a SF-36 vitality domain sub-analysis of the MYCYC and RITUXIVAS studies226. 964 
Furthermore, there were marked disparities in physical QOL, including reduced knee extension 965 
(76%) among patients with AAV compared with healthy controls. This reduced knee extension 966 
was associated with impaired SF-36 Physical Component Score, as were metrics of pre-existing 967 
muscle strength227. 968 
 Since QOL differs for each patient, QOL can also be helpful in developing more 969 
personalized treatment approaches. Studies examining whether physical activity improves 970 
fatigue in patients with AAV are underway228. As disease assessment in AAV should include 971 
function or QOL167, reliable PRO tools are crucial not only for monitoring individual patients 972 
but also for high quality assessment of the impact of AAV and the success of its therapies. 973 
  974 
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[H1] Outlook 975 
 Substantial progress has been made in understanding and treating AAVs. GPA, MPA and 976 
EGPA have gone from diseases with a high mortality within 1–2 years of the onset of symptoms 977 
to chronic conditions that require lifelong specialist management. However, major challenges 978 
remain. AAVs are still responsible for substantial morbidity and mortality, both from the 979 
diseases themselves and from their treatments. Most treatments are fairly non-specific and come 980 
with undesirable immune and metabolic adverse effects. Furthermore, the optimal duration of 981 
therapy is uncertain, in part because of a lack of reliable predictors of relapse. More effective 982 
management of AAV in the future will rely on a better understanding of the clinical aspects of 983 
the disease and of disease-causing processes, together with the development of effective 984 
biomarkers to better define disease activity and predict relapse. More precise, effective and less 985 
toxic treatments require better knowledge, continued recognition of unmet clinical need, and 986 
additional strategic and successful well-designed international collaborative clinical trials. These 987 
efforts must be combined with more explicit recognition of important patient-centred outcomes, 988 
both in trials and in clinical practice. EGPA, as an even less common form of AAV with 989 
different clinical features to GPA and MPA, poses great challenges. In EGPA, even more than in 990 
GPA and MPA, multidisciplinary and international collaborations are required to improve the 991 
lives of people with this disease. Table 4 summarizes some of the emerging therapies and 992 
biomarkers in AAV. 993 
 Better diagnostic and classification criteria of AAV will assist understanding, clinical 994 
studies and improvements in patient care. The near-complete DCVAS has developed data-995 
driven classification criteria for systemic vasculitides and should provide improved 996 
standardized criteria. Furthermore, while EGPA is clearly a distinct disease entity, for GPA 997 
and MPA the relationships and overlap between the syndromic classifications (GPA and 998 
MPA), and the presence of autoreactivity to either PR3 or MPO must be more clearly 999 
understood to aid progress in understanding, in clinical trial design and in management 1000 
strategies. These efforts are not only important for improved induction therapies, but also for 1001 
defining treatment duration and the management of relapse. 1002 
 Epidemiologically, there is inadequate data pertaining to EGPA in general, as well as a 1003 
clear need to define the occurrence of all AAV types in Africa and South Asia. A better 1004 
definition of the nature and burden of disease is likely to improve clinical care and outcomes, 1005 
while more detailed understanding of the epidemiological associations will inform disease 1006 
pathogenesis. The recognition that AAV is an autoimmune condition and the role of ANCAs in 1007 
effecting injury have been major advances. Nonetheless, the complexity of AAV and the 1008 
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inadequacies of current therapies demand a more detailed understanding of pathogenesis. Many 1009 
questions remain. Can the understanding of the genetics of AAV, including EGPA, lead to 1010 
pathway-directed therapies, either via new therapies or by repurposing existing therapeutics? 1011 
Why are only some ANCAs pathogenic – and if we understand this, can we measure specific 1012 
ANCA subtypes to develop more effective biomarkers? As there is substantial deposition of 1013 
ANCA antigens in affected tissues, why is immunoglobulin deposition not more prominent? 1014 
Why are some organs and tissues preferentially affected? Why do some individuals lose 1015 
tolerance to PR3 or MPO, whereas most do not, when these neutrophil proteins are frequently 1016 
released in an immunologically ‘dangerous’ infectious and inflammatory context? Can 1017 
immunological tolerance be re-established by antigen-specific immunomodulation? Although 1018 
much is known about events in the acute effector phase of injury, key events in more chronic 1019 
disease and the role of T and B cell memory are unclear. Better understanding of these issues has 1020 
the potential to move the goalposts in developing treatments that induce long lasting remission 1021 
and tolerance. 1022 
 Key uncertainties in the care of patients with AAV include the optimal duration and 1023 
intensity of maintenance therapy in an individual patient, and a lack of biomarkers that signal 1024 
relapses. Better biomarkers, either singly or in combination, to predict severity and relapse risk 1025 
would lead to a more precise treatment approach. Emerging biomarkers include urinary sCD163, 1026 
which could be useful in determining renal relapse, with or without other markers164,229. 1027 
Following from observations that the risk of relapse in a patient with AAV is associated with an 1028 
‘active’ T cell signature associated with the reduced expression of genes associated with T cell 1029 
exhaustion136, prospective clinical trials are underway to determine whether markers of this 1030 
signature can inform treatment intensity. Other potential biomarkers are emerging and are 1031 
undergoing further evaluation165. 1032 
 The potential for complement inhibition (by targeting the C5a receptor) is one of several 1033 
therapeutic strategies aimed at limiting neutrophil activation. Complement inhibition therapies 1034 
could reduce or replace the current reliance on glucocorticoids in induction therapy regimens, as 1035 
in phase II and III trials of C5aR inhibition110,111. Glucocorticoids are a pillar of maintenance 1036 
therapy for many patients and this reliance needs to be mitigated. In EGPA, further clinical trials 1037 
in IL-5/IL-5R blockade will hopefully improve therapeutic options in this disease. Much 1038 
attention has justifiably been given to ANCA–neutrophil mediated events in AAV, but the more 1039 
selective inhibition of the underpinning T and B cell autoimmunity also has potential in inducing 1040 
and maintaining remission. The goal in the treatment of AAV is not only to supress disease, but 1041 
also to restore tolerance. Currently, there are no clear markers of tolerance to reassure clinicians 1042 
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and patients when ceasing immunosuppression and that can be used as surrogate markers in 1043 
trials of new tolerogenic, curative therapies. Whereas tolerogenic strategies that have been 1044 
applied to other diseases might be suitable for AAV, outcome measures in AAV are unclear, 1045 
although at least in the case of MPO, progress has been made in defining key epitopes. 1046 
 A multidisciplinary approach and patient engagement would result in a more integrated 1047 
treatment strategy and improved outcomes in these complex multisystem diseases. Clinicians 1048 
and patients should work together in a clinical setting to increase involvement of patients in their 1049 
own care and treatment decisions. There are several dimensions to this issue. The educational 1050 
needs of patients newly diagnosed with AAV are high, and the rarity of the conditions makes 1051 
meeting these needs complicated. In the clinical trial environment, the use of PRO measures, 1052 
such as AAV-PRO, should be mandatory. Interventional trials including outcome measures that 1053 
focus on improving physical and mental QOL are just beginning228. AAVs are challenging and 1054 
complex conditions but, with an integrated, collaborative approach that includes considerable 1055 
patient involvement, great progress can be made in improving the lives of people with these 1056 
diseases. 1057 
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Display items 1085 
Table 1. Comparisons of the three syndromic presentations of AAV  1086 
 GPA MPA Eosinophilic GPA 
Incidencea 0.4–11.9 cases per 1 
million person-years 
0.5–24.0 cases per 1 
million person-years 
0.5–2.3 cases per 1 million 
person-years 
Prevalencea 2.3–146.0 cases per 1 
million persons 
9.0–94.0 cases per 1 
million persons 





45–65 55–75 38–54 
Male: 
Female 







involving the upper and 




(such as capillaries, 
venules, arterioles, arteries 
and veins). Necrotizing 
glomerulonephritis is 
common. 
Necrotizing vasculitis, with 
few or no immune 
deposits, predominantly 
affecting small vessels 
(such as capillaries, 
venules, or arterioles). 
Necrotizing arteritis 
involving small and 
medium arteries may be 
present. Necrotizing 
glomerulonephritis is very 
common. Pulmonary 
capillaritis often occurs. 
Granulomatous 




involving the respiratory 
tract; necrotizing vasculitis 
predominantly affecting 
small to medium vessels; 
associated with asthma and 
eosinophilia. ANCA is 

















Neutrophil Neutrophil Eosinophil 
Relapse 
rate 
Higher than MPA (or 
MPO-AAV) 
Lower than GPA (or 
PR3-AAV) 
Relapse is frequent 
 
1087 
ANCA, anti-neutrophil cytoplasmic antibody; CHCC, Chapel Hill Consensus Conference; 1088 
GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; MPO, 1089 
myeloperoxidase; PR3, proteinase 3. 1090 
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Table 2. Key clinical trials of therapies for GPA and/or MPA  1 
Name Population Intervention Key result Other findings 
Induction therapy 
CYCLOPS193,194 Newly diagnosed 
GPA or MPA, 
renal involvement, 
ANCA+a or 
ANCA– if biopsy 
IV versus oral 
CYC, plus GCs 
IV non-






dose with IV 
vs oral CYC 
Decreased 
relapse with 
oral CYC (HR 
0.50) at long-
term follow up 
CORTAGE230 New diagnosis, age 
≥65 yearsb 
IV-CYC 
(maximum 6 x 
500 mg, every 
2-3 weeks) plus 
9 months GCs 
versus IV CYC 
(~5.5g) plus 26 






with lower dose 
CYC and GCs  
RAVE195,196 GPA or MPA 
newly diagnosed or 
relapsing, ANCA+, 
SCr <353 µmol/l 
RTX versus 



























MEPEX201,232 GPA or MPA with 
biopsy proven 
glomerulonephritis, 
SCr >500 µmol/l, 
ANCA+ or ANCA– 
PLEX versus 
IV-MP as add 







at 3 months 
and renal 








GPA or MPA 
newly diagnosed or 
relapsing with renal 
involvement 
(eGFR <50 




a) PLEX as add 
on to CYC or 




plus RTX or 
CYC 










CLEAR110 Phase II, newly 
diagnosed or 
relapsing GPA or 




reduced GCs or 
no GCs, versus 












Phase III, newly 
diagnosed or 




plus RTX or 











IVIg202 Active GPA or 
MPA, >2 months 
CYC and GCs, 
ANCA+ 
CYC and GCs 
versus add-on 
IV-Ig (single 




Effects did not 
extend beyond 
3 months 
NORAM199,234 Newly diagnosed 
GPA or MPA, less 















with MTX  
MYCYC200 New diagnosis of 



















GPA or MPA, SCr 
<500 µmol/l, 
ANCA+ or ANCA– 
if biopsy 
Induction oral-
CYC or GCs 3–










GPA than MPA 
WEGENT236,237 GPA or MPA in 
remission, initially 
treated with IV 
CYC and GCs, 
ANCA+ or ANCA– 



























or ANCA– with 
biopsy 
AZA or GCs 














GPA or MPA in 
remission after 
CYC and GCs, 
ANCA+ 






AZA at 28 
months (HR 
6.61) 
Similar rates of 
adverse events 
Decreased 





















GPA or MPA, 
sustained 







versus 2 further 












Relapsed GPA or 
MPA re-induced 
with RTX and 
GCs, in remission, 
ANCA+ 







No increase in 
adverse events 
with RTX  
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WGET240 GPA with active 
disease,  


























effects at 30 mg 
dose 
BREVAS242 GPA or MPA in 
















planned due to 
change in 
clinical practice 
Stegeman et al.243 GPA in remission, 















a ANCA+ refers to a positive test at any time, not ANCA+ at the time of entry into study. 3 
b Study also included polyarteritis nodosa (10 patients) and EGPA (14 patients), of the 104 4 
patients. 5 
cSeveral treatment pathways were available, depending on the severity and activity of disease 6 
and other factors, but usually involved either MTX + GCs, then taper and try to cease GCs; or 7 
oral CYC and GCs, then MTX or AZA taper and try to cease GCs. 8 
AAV, ANCA-associated vasculitis; AZA, azathioprine; CYC, cyclophosphamide; eGFR, 9 
estimated glomerular filtration rate; GCs, glucocorticoids; GPA, granulomatosis with 10 
polyangiitis; FFS, Five Factor Score; HR, hazard ratio; LEF, leflunomide; MMF, 11 
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mycophenolate; MPA, microscopic polyangiitis; MTX, methotrexate; OR, odds ratio; PLEX, 12 
plasma exchange; PR3, proteinase 3; RTX, rituximab; SCr, serum creatinine; TNF, tumour 13 
necrosis factor. 14 
  15 
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Table 3. Key clinical trials of therapies for EGPA  16 
 17 
Trial Population Intervention (n) Key result Other findings 
Ribi et al.244 Treatment failure or 




GCs and IV-CYC 
(10) versus GCs 




5/10, AZA 7/9 








GCs (25) versus 
add-on AZA (26)  










MIRRA143,210 Relapsing or 
refractory EGPA, 
stable GC dose 
(7.5–50 mg) 
GCs (68) versus 
add-on SC-
mepolizumab every 
four weeks for 52 
weeks (68)  
Mepolizumab 
effective, mainly in 
allergy related 
manifestations 
Post hoc analysis suggests 






GCs versus add-on 
PLEX (18 in total)  
No benefit, results 
grouped together 
with patients with 
PAN 
Reflects historical 





IV-CYC and GCs 
(6) versus add-on 
PLEX (8)  
No benefit, results 
grouped together 
with patients with 
PAN 
Reflects historical 
grouping of disease 
 18 
AAV, ANCA-associated vasculitis; AZA, azathioprine; CYC, cyclophosphamide; EGPA, 19 
eosinophilic granulomatosis with polyangiitis; FFS, Five Factor Score; GCs, glucocorticoids; 20 
PAN, polyarteritis nodosa; PLEX, plasma exchange; SC, subcutaneous. 21 
  22 
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Table 4. Selected potential new management strategies and biomarkers in AAVa 23 
 Potential strategy Stage of development 
Treatments   
Complement 
inhibition 
Avacopan (small-molecule C5a 
receptor antagonist)110 
Phase III trial completed 
(NCT02994927)111 
SYK inhibition Small-molecule inhibitors248 Pre-clinical model proof of 
concept studies (MPO-AAV) 
Eosinophils and Th2 
cells in EGPA 
Direct or indirect targeting of 
eosinophils and TH2 cellsb, for 
example anti-IL-5R 
(benralizumab), Th2 and 
eosinophil chemokines 
Non-inferiority clinical trial 
comparing mepolizumab with 
benralizumab (NCT04157348) 
BAFF inhibition Belilumab242 as add on to 
rituximab 




Abatacept249 Phase II trial in progress 
(NCT02108860) 
T cell or TH cell 
defining cytokine 
inhibition 
Monoclonal antibodies, for 
example ustekinumab (anti-IL-
12p40)121,218  
Pre-clinical model proof of 
concept studies published (MPO-
AAV)121,250 
Tolerogenic therapies Peptide and antigen tolerogenic 
platforms 
Pre-clinical model proof of 
concept studies published251 
(MPO-AAV) 
Biomarkers   
Renal activity or flare Urinary soluble CD163 with or 
without other biomarkers (for 
example, soluble CD25, 
CCL2)164,229  
Further clinical studies for 
biomarker utility 
Overall risk of flare Markers of T cell activity and 
exhaustion in AAV135,136  
Trials of 17 gene qPCR 
stratification for prognosis in other 
diseases 252 
Impending flare CD5+ B cells253,  Clinical studies, NCT03906227 
aOnly those for which a rationale has been established are included. 24 
bIn addition to anti-IL-5 strategies already in clinical use. 25 
BAFF, B cell-activating factor; EGPA, eosinophilic granulomatosis with polyangiitis; qPCR, 26 
quantitative polymerase chain reaction; SYK, spleen tyrosine kinase. 27 
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Figure legends 1 
Figure 1. Small vessel vasculitis. a | The updated 2012 Chapel Hill Consensus Conference 2 
classification of vasculitis144, which is based on the size of the main vessels that are affected. 3 
The anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides, namely 4 
granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic 5 
granulomatosis with polyangiitis (EGPA), are small vessel vasculitides. b | Patterns of ANCA 6 
staining by indirect immunofluorescence. A cytoplasmic pattern of staining for ANCA 7 
(cANCA) is strongly associated with antibodies against PR3. A perinuclear pattern of staining 8 
for ANCA (pANCA) is seen with antibodies against several different proteins, but anti-MPO 9 
antibodies are most relevant for AAV. Part a is adapted with permission from [add publisher 10 
here with permission] (REF 144). Scale bar = 10 µm.  11 
 12 
Figure 2. Global epidemiology of ANCA-associated vasculitides. The map depicts studies that 13 
have examined the incidence of granulomatosis with polyangiitis (GPA) and microscopic 14 
polyangiitis (MPA) per 1 million individuals per year. There is substantial variation in the 15 
relative incidences of GPA and MPA between Europe and Asia, and an effect of latitude. The 16 
regions studied include Australia254; Canada255; Germany256; Greece257; Japan258; Lithuania259, 17 
Turkey260; Peru261; Spain (Lugo)262; Spain (Malaga)263; Sweden264; United Kingdom18; USA 18 
(Minnesota)2; USA (Western Montana)265; and the West Bank266. 19 
 20 
Figure 3. Pathogenetic events in GPA and MPA. Simplified schematic showing events 21 
leading to acute tissue injury in two forms of anti-neutrophil cytoplasmic antibody (ANCA)-22 
associated vasculitis (AAV), namely granulomatosis with polyangiitis (GPA) and microscopic 23 
polyangiitis (MPA). Risk factors for loss of tolerance and disease (pink) include genetic and 24 
environmental factors, age, and infection or inflammation. These AAVs involve autoreactive 25 
elements (blue), including effector cell responses to the neutrophil proteins proteinase 3 (PR3) 26 
and myeloperoxidase (MPO) by autoreactive T cells and B cells, with the humoral response 27 
resulting in the production of ANCAs. The key steps in the effector phase (green) are neutrophil 28 
priming and activation by ANCA with subsequent neutrophil localisation to the 29 
microvasculature and injury. MPO and PR3 are deposited in and around the microvasculature of 30 
target tissues and effector T cells recognise these antigens, resulting in pro-inflammatory 31 
cytokine production and further recruitment of effector leukocytes. These responses lead to 32 
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tissue injury and endothelial damage (red). Less is known about the pathogenesis of the other 33 
form of AAV, namely eosinophilic GPA (EGPA), than for GPA and MPA. 34 
 35 
Figure 4. Loss of tolerance and the generation of effector responses in GPA and MPA. 36 
Genetic risk factors in an ageing host combine with known or unknown environmental factors 37 
(possibly including silica, certain medications or drugs) and potentially infection to induce a loss 38 
of T and B cell tolerance to one of two clinically recognized neutrophil antigens, proteinase 3 39 
(PR3) or myeloperoxidase (MPO). Autoantigen-specific T cells become activated and 40 
differentiate into T helper (TH) cells, including T follicular helper (TFH) cells that provide help to 41 
B cells, type 1 T helper (TH1) cells and IL-17-producing TH17 cells; an exhausted phenotype is 42 
associated with a lower risk of disease relapse. B cells differentiate into plasma cells and 43 
memory cells. Plasma cells secrete autoantibodies against PR3 (PR3-ANCA) or MPO-ANCA. 44 
Neutrophils are activated and primed by pro-inflammatory cytokines, pattern-associated 45 
molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs), and binding of 46 
C5a to the C5a receptor on neutrophils. ANCAs bind to neutrophils in an antigen-specific and 47 
Fcg receptor (FcgR)-dependent fashion to neutrophils and monocytes. BAFF, B cell-activating 48 
factor; Breg cells: regulatory B cells; NET: neutrophil extracellular trap; TLR: Toll-like receptor; 49 
TNF: tumour necrosis factor; Treg cells: regulatory T cells. GPA, granulomatosis with 50 
polyangiitis; MPA, microscopic polyangiitis. 51 
 52 
Figure 5. Endothelial and tissue injury in GPA and MPA. Anti-neutrophil cytoplasmic 53 
antibody (ANCA)-activated, primed neutrophils localize to the endothelial cells in the 54 
microvasculature of the kidneys, respiratory tract and other tissues. Recruitment is mediated by 55 
adhesion molecules and chemokines. Adherent neutrophils induce endothelial injury by several 56 
mechanisms. They produce reactive oxygen species (ROS) and degranulate, releasing proteases 57 
and ANCA antigens. They generate neutrophil extracellular traps (NETs) and undergo cell death 58 
by NETosis. ANCA antigens released by neutrophils and when in a complex with major 59 
histocompatibility complex class II (MHC-II) or MHC-I can be recognized as antigenic peptides 60 
by effector T helper 1 (TH1) cells, IL-17 producing T helper (TH17) cells and CD8+ T cells, at 61 
least in the case of myeloperoxidase (MPO). Antigen-presenting cells can include endothelial 62 
cells, intravascular monocytes and dendritic cells (DCs). Cytotoxic CD4+ T cells expressing 63 
NKG2D recognize MHC-I-polypeptide-related sequence A (MICA), which is upregulated on 64 
activated endothelial cells and in granulomas. Mechanisms of extravascular tissue injury include 65 
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the extravasation of inflammatory leukocytes, the formation of B cell aggregates that may 66 
present ANCA antigens to T cells, produce pro-inflammatory cytokines and produce ANCA in 67 
situ. Tissue-resident and recruited DCs present antigen, whereas tissue-resident and recruited 68 
macrophages are pro-inflammatory and pro-fibrotic. These macrophages shed soluble CD163 69 
(sCD163), which is a potential biomarker of disease activity. Leukocytes within granulomas 70 
contribute to inflammatory injury. Ag, antigen; DAMPs, danger-associated molecular patterns; 71 
FcgR, Fcg receptor; ICAM1, intercellular adhesion molecule 1; PAMPs, pattern-associated 72 
molecular patterns; ROS, reactive oxygen species; TLR, Toll-like receptor; VCAM1, vascular 73 
cell adhesion protein 1. 74 
 75 
Figure 6. Clinical features of AAV. a | Schematic showing the organs, organ systems and 76 
tissues that are affected in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides 77 
(AAVs). The approximate relative frequency of involvement is also shown. b | Radiological 78 
features of sinonasal disease in AAV. Coronal CT images showing (left) destruction of the nasal 79 
septum, inferior turbinates and right middle turbinate (arrowheads) in a patient with newly 80 
diagnosed GPA; (right) chronic changes in sinonasal GPA showing simultaneous nasal septum 81 
destruction (white arrowhead) and neo-osteogenesis (black arrowhead). b | Radiological features 82 
of pulmonary hemorrhage in acute AAV. Chest X-ray (left) showing infiltrates and changes 83 
consistent with acute pulmonary haemorrhage; (right) transverse CT image showing acute 84 
pulmonary haemorrhage and “ground-glass” changes (*). =, rate of involvement approximately 85 
equal to; <, rate of involvement more frequent than; <<, rate of involvement substantially more 86 
frequent than; EGPA, eosinophilic granulomatosis with polyangiitis; GPA, granulomatosis with 87 
polyangiitis; MPA, microscopic polyangiitis. aFor EGPA, asthma and allergic manifestations are 88 
included in the frequency of involvement. Parts b and c courtesy of Dr Ken Lau and A/Prof 89 
Joanne Rimmer, Monash Health and Monash University. 90 
 91 
Figure 7. Histopathology of AAV. a | Fibrinoid vessel wall necrosis (N) is the hallmark of 92 
AAV, accompanied by a ‘granuloma-like’ mixed inflammatory infiltrate (circled) composed of 93 
macrophages, lymphocytes, plasma cells and granulocytes in microscopic polyangiitis (MPA). 94 
b | Resolution of inflammation leads to transmural (<) fibrous scars (F) and substantial 95 
narrowing (*) or even complete occlusion of the vessel lumen. c | ‘Geographic’ necrosis (N) of 96 
confluent epithelioid granulomas in the lungs in granulomatosis with polyangiitis (GPA). Inset 97 
shows a subepithelial nasal granuloma in GPA, composed of loose aggregates of epitheloid cells 98 
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and giant cells. d | Epithelioid granulomas (circled) in eosinophilic GPA (EGPA) in the nose are 99 
more compact and are surrounded by eosinophils. e | Early lesions in the lung in MPA often only 100 
show neutrophilic capillaritis (C) and fibrinous exudates (*). f | Giant cells with sometimes 101 
‘smudged’ appearing nuclei (>), neutrophilic granulocytes and nuclear debris (*) from 102 
neutrophils in epithelioid granulomas in the lungs in GPA. g | Necrosis of glomerular capillaries 103 
(N) is seen adjacent to an unaffected glomerulus (G) in MPA. h | Lesions of different age are 104 
seen with partial or circumferential crescents and variable destruction of the Bowman capsule 105 
(>) in MPA. i | Neutrophilic capillaritis (C) and multinucleated giant cells (GC) are characteristic 106 
features of GPA in the nasal mucosa. Staining methods are haematoxylin and eosin (parts a–f) 107 
acid fuchsin orange G (part g); Periodic acid–Schiff (part h) and Giemsa (part i). 108 
 109 
Figure 8. Management of GPA and MPA cases that present with organ or life-threatening 110 
manifestations. a | Current treatment approaches include an induction phase to induce 111 
remission, followed by a maintenance phase, then long-term follow up. b | Current induction 112 
treatment regimens for several diseases are centred on glucocorticoids (GCs), in combination 113 
with either cyclophosphamide (CYC) or rituximab (RTX). Intravenous GCs are often 114 
administered after treatment with high-dose oral prednisolone (or prednisone) at an initial dose 115 
of 50–75 mg. GC dose is tapered over several months, with the standard of care being the 116 
quicker taper used in the PEXIVAS trial191. The optimal duration of GC therapy in the 117 
maintenance phase of AAV is unclear, but GCs are often withdrawn over 4–36 months. CYC is 118 
recommended for induction, for between 3–6 months, and can be administered by intravenous 119 
pulse or daily oral therapy, with a switch to maintenance therapy at remission (3–6 months). 120 
Rituximab can also be given for induction therapy in 2–4 doses and is increasingly being used in 121 
preference to CYC. RTX is given for maintenance therapy, after induction with RTX or CYC. 122 
Oral immunosuppressive agents, including azathioprine (AZA), methotrexate (MTX) or 123 
mycophenolate mofetil (MMF), are alternatives for RTX for maintenance therapy. MTX or 124 
MMF are alternatives to CYC or RTX for induction therapy in non-organ threatening disease. c | 125 
Disease state corresponding with phase of therapy in parts a and b. Some patients do not respond 126 
to one of the standard induction regiments and develop refractory disease, whereas others 127 
relapse while on or after maintenance therapy is halted, and therefore require re-initiation of 128 
induction therapy.  129 




Box 1. Diagnostic testing methods in AAV  132 
 Most cases of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis 133 
(MPA) are characterized by anti-neutrophil cytoplasmic antibodies (ANCAs) directed against 134 
either proteinase 3 (PR3) or myeloperoxidase (MPO). Two methods have been used to detect 135 
these antibodies in clinical practice, namely indirect immunofluorescence (IIF) and various 136 
antigen-specific immunoassays, most commonly enzyme-linked immunosorbent assays 137 
(ELISAs). 138 
 139 
Indirect immunofluorescence 140 
 This technique involves incubating diluted patient serum samples with ethanol-fixed and 141 
permeabilized neutrophils from healthy donors, which in some assays are pre-attached to glass 142 
slides. Bound ANCA is then detected using a fluorescent secondary anti-human IgG antibody, 143 
and the presence, titre and pattern of fluorescence are assessed by fluorescence microscopy. 144 
There are two primary patterns of fluorescence that are relevant to the diagnosis of AAV (Figure 145 
1c): 146 
• cANCA: a cytoplasmic pattern of ANCA staining, which is strongly associated with anti-147 
PR3 antibodies (PR3-ANCA) 148 
• pANCA: a perinuclear pattern of ANCA staining, which in AAV is strongly associated 149 
with anti-MPO antibodies (MPO-ANCA). The perinuclear pattern is a consequence of 150 
the ethanol fixation of neutrophils, as the highly cationic MPO localizes around the 151 
negatively charged cell nucleus after ethanol fixation. 152 
 153 
Antigen-specific assays for PR3-ANCA and MPO-ANCA 154 
 The most commonly used assays are ELISAs specific for either PR3-ANCA or MPO-155 
ANCA. Improvements in antigen-capture methods have resulted in better assay performance. In 156 
addition, several other types of solid-phase antigen-specific assays may be used to detect PR3-157 
ANCA and MPO-ANCA161. 158 
 Approaches to ANCA testing when the diagnosis of AAV (that is, GPA, MPA or EGPA) 159 
is suspected are informed by consensus statements, but there is substantial variation in 160 
practice267. With improved immunoassay performance, the approach recommended by an 161 
international consensus statement161 after a large multicentre study268 is to use antigen-specific 162 
assays for PR3-ANCA and MPO-ANCA as the initial screening method when AAV is 163 
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suspected, with IIF only performed if these assays are negative. Approaches based on 1999 164 
guidelines269, which are still used in some diagnostic laboratories, involve a combination of IIF 165 
screening with specific PR3-ANCA and MPO-ANCA ELISAs for positive samples, or using 166 
both methods for each sample. 167 
 Although ANCAs are primarily associated with AAVs, a positive ANCA test by IIF 168 
occurs in other diseases, including: 169 
• Infections, including infective endocarditis, where PR3-ANCA or MPO-ANCA can 170 
occur270-272, an important differential diagnosis, as misdiagnoses result in unwarranted 171 
immunosuppression with life-threatening consequences. ANCA may be present in other 172 
chronic infections, including tuberculosis, and Pseudomonas aeruginosa infection in 173 
individuals with cystic fibrosis273,274. 174 
• Gastrointestinal tract diseases273, including ulcerative colitis and liver disease, such as 175 
autoimmune hepatitis, primary biliary sclerosis, primary sclerosing cholangitis and viral 176 
hepatitis. The ANCA pattern in these conditions resembles, but differs from, the pANCA 177 
pattern and is described as atypical ANCA (aANCA). In ulcerative colitis, PR3-ANCA is 178 
present, but is uncommon. 179 
• Other autoimmune diseases, such as systemic lupus erythematosus and rheumatoid 180 
arthritis (notwithstanding the co-existence of AAV or AAV-like features in a small 181 
minority of people with these diseases). 182 
• Drug-associated AAV is associated not only with MPO-ANCA but also anti-lactoferrin 183 
and anti-neutrophil elastase antibodies. 184 
Other proteins associated with a positive IIF ANCA test in these diseases include azurocidin, 185 
bactericidal/permeability increasing protein and cathepsin G. Their clinical utility is unproven 186 
and antigen-specific testing is not routinely performed in AAV. Besides PR3 and MPO, other 187 
antigens may be relevant to AAV, but are not currently tested for in routine clinical practice. 188 
  189 
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Box 2. Clinical features of the ANCA-associated vasculitides  190 
Granulomatosis with polyangiitis (GPA) 191 
 Symptoms of systemic vasculitis, such as fever, weight loss, malaise and fatigue. 192 
Symptoms and signs of small vessel vasculitis, often in the ear, nose and throat (ENT) tract 193 
(nasal and oral ulcers and crusting, nose bleeds, nasal polyps, paranasal sinusitis, cartilaginous 194 
destructions with granulomas on biopsy, hearing impairment and otorrhea), the eyes 195 
(conjunctival injection, eye pain, diplopia, proptosis, uveitis and retroorbital mass), the airways 196 
and lungs (hoarseness, cough, dyspnoea, stridor, pleuritic pain, pulmonary nodules, infiltrates, 197 
cavities and haemorrhage with granulomatous inflammation on biopsy), the kidneys (urinary 198 
abnormalities, elevated serum creatinine with variable degrees of proteinuria and rapidly-199 
progressing pauci-immune glomerulonephritis on biopsy), the peripheral nervous system 200 
(mononeuritis) and the skin (purpura, focal necrosis, ulcers and leukocytoclastic vasculitis on 201 
biopsy). 202 
 203 
Microscopic polyangiitis (MPA) 204 
 Symptoms of systemic vasculitis, such as fever, weight loss, malaise, and fatigue. 205 
Symptoms and signs of small vessel vasculitis are as for GPA, but without granulomatous 206 
inflammation on biopsy. ENT tract manifestations are as in GPA but less frequent. The kidneys 207 
(rapidly progressing necrotizing pauci-immune glomerulonephritis) and the skin (necrotizing 208 
leukocytoclastic vasculitis) are commonly affected. 209 
 210 
Eosinophilic granulomatosis with polyangiitis (EGPA) 211 
 Many but not all individuals with EGPA have clear features of vasculitis. Symptoms of 212 
systemic vasculitis include fever, weight loss, malaise, fatigue and lymphadenopathy. Small 213 
vessel vasculitis of skin, peripheral nervous system, kidneys, heart, and gastrointestinal tract 214 
occurs. Cardiac involvement, including cardiomyopathy, contributes considerably to mortality in 215 
EGPA. Asthma is a near universal feature of EGPA and usually precedes vasculitis. Pulmonary 216 
infiltrates and >10% eosinophilia in peripheral blood are common. ENT involvement is frequent, 217 
including serous otitis media, allergic rhinitis, nasal obstruction, recurrent sinusitis and nasal 218 
polyposis.  219 
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Box 3: Drug induced vasculitis 220 
A variety of drugs are associated with ANCA+ vasculitis, with at least some features of 221 
AAV. Propylthiouracil (PTU) and to a lesser degree some other antithyroid drugs is relatively 222 
commonly associated with MPO-ANCA, with some people developing an MPA-like 223 
vasculitis275. Other drugs, including hydralazine (an anti-hypertensive vasodilator), minocycline 224 
(a tetracycline antibiotic), and cocaine adulterated with the antihelminthic agent levamisole are 225 
associated with ANCA+ vasculitis276. Leukotriene antagonists have been implicated in EGPA, 226 
though causality is unclear277. The therapeutic agents associated with ANCA+ vasculitis have 227 
been listed in detail elsewhere275. The epidemiology of drug induced vasculitis largely reflects 228 
patterns and frequency of use of these drugs in different populations (for example, PTU is 229 
widely used in China, while cocaine/levamisole is more common in the USA). 230 
Clinically, a pANCA pattern is most common, but concurrent pANCA and cANCA 231 
positivity is common in cocaine/levamisole induced disease. Autoantibody specificities include 232 
MPO-ANCA, as well as other, non-classical ANCA antigens such as lactoferrin and neutrophil 233 
elastase (Box 2)275,276. Patients are often younger. Clinical manifestations can mimic AAV but 234 
are often less severe. Skin involvement may be more prominent, variant in nature and severe, 235 
particularly with cocaine/levamisole, and neutropenia can be present in vasculitis secondary to 236 
PTU or cocaine/levamisole. Anti-nuclear antibodies may be present, and hydralazine and 237 
minocycline are both associated with a lupus-like phenotype. 238 
The mechanisms that underpin drug induced vasculitis are unclear, though some clues 239 
exist. Levamisole and minocycline have immunomodulatory effects. PTU inhibits thyroid 240 
peroxidase that has sequence homology to MPO. Due to this homology, it alters the structure 241 
and function of MPO in rats275,278. Furthermore, PTU induces abnormal NET formation from 242 
human neutrophils in vitro and MPO-AAV in vivo in rats279. These data, as well as 243 
cocaine/levamisole’s effects on NET formation280 support abnormal or aberrant autoantigen 244 
exposure as a factor in the development of AAV. 245 
Recognition of drug induced vasculitis via an appropriate index of clinical suspicion, 246 
obtaining a medication history and enquiring as to illicit drug use, potentially with urinary 247 
screening, is central to the management of these conditions. Ceasing the potential offending 248 
agent may itself result in improvement. However, immunosuppression may be required and 249 
severe, organ threatening disease can occur. Re-challenge with the suspected drug for diagnostic 250 
reasons is not recommended. 251 
  252 
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Box 4. A patient’s experience of AAV  253 
Being diagnosed with a rare and potentially life-threatening disease is something that no one 254 
expects to happen to them. Many patients with AAV have substantial delays in time to diagnosis 255 
and may have had serious hospitalizations and organ damage by the time they are diagnosed. 256 
But once the initial crisis is over, the ongoing work to achieve and maintain remission begins. It 257 
is important to note that AAV is typically a life-long chronic condition that will require constant 258 
vigilance by patients and their doctors. Fortunately, there have been new treatment options for 259 
AAV in recent years, especially new biologic therapies. However, these medications have little 260 
or no impact on the fatigue and pain caused by AAV. Thus, while patients may be ‘in remission’ 261 
with the help of ongoing immunosuppressive therapy, many of us still feel the relentless effects 262 
of this fatigue and pain on a daily basis. Patients also worry about the potential adverse effects 263 
from the treatments and the balancing of toxicity from the treatment against damage from the 264 
vasculitis itself. Better treatments for AAV are needed, especially less toxic substitutes for 265 
glucocorticoids. But also needed are better ways to measure disease activity, such as biomarkers 266 
that will distinguish our flares from symptoms caused by other things, such as treatment toxicity 267 
or infections. In addition, urgently needed are treatment options for symptoms that have a major 268 
impact on our quality of life, such as fatigue and pain, which often remain unaddressed. Greater 269 
patient input on setting treatment priorities will help focus attention on our unmet quality of life 270 
needs. 271 
 272 
Jennifer Gordon, PhD. Dr. Gordon has EGPA and serves on the Vasculitis Foundation Vasculitis 273 
Patient-Powered Research Network. 274 
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